



- (51) **International Patent Classification:**
G01N 33/487 (2006.01) C12Q 1/68 (2006.01)
- (21) **International Application Number:**
PCT/IB2016/001841
- (22) **International Filing Date:**
8 December 2016 (08.12.2016)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/264,709 8 December 2015 (08.12.2015) US
- (71) **Applicant:** KATHOLIEKE UNIVERSITEIT LEUVEN
KU LEUVEN RESEARCH & DEVELOPMENT
[BE/BE]; Waaistraat 6 -box 5105, LEUVEN B-3000 (BE).
- (72) **Inventors:** MAGLIA, Giovanni; Carry Van Bruggeweg
53, 9408 DX Assen (NL). FRANCESCHINI, Lorenzo;
Koning Leopold I-straat 22, 1, 3000 Leuven (BE).
BROUNS, Tine; 2de Carabinierslaan 64, 3620 Lanaken
(BE).
- (74) **Agent:** TUXWORTH, Pamela Mary; J A Kemp & Co, 14
South Square, Gray's Inn, London WC1R 5JJ (GB).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,


BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

- (54) **Title:** MODIFIED NANOPORES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF

**FIG. 20**

- (57) **Abstract:** Provided herein relate to modified or mutant forms of cytolysin A (ClyA) and compositions comprising the same. In particular, the modified or mutant forms of ClyA permits efficient capture and/or translocation of a target negative-charged molecule or polymer through the modified or mutant ClyA nanopores at low or physiological ionic strengths. Thus, methods for using the modified or mutant forms of ClyA and compositions, for example, for characterizing a target negatively-charged analyte, e.g., a target polynucleotide, are also provided.

MODIFIED NANOPORES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application number 62/264,709 filed December 8, 2015, the contents of which are incorporated by reference herein in their entirety.

TECHNICAL FIELD

10 Provided herein are modified or mutant forms of cytolysin A (ClyA) and compositions comprising the same. Methods for using the modified or mutant forms of ClyA and compositions, for example, for characterizing a target analyte, *e.g.*, a target polynucleotide, are also provided.

BACKGROUND

15 Transmembrane pores (*e.g.*, nanopores) have been used to identify small molecules or folded proteins and to monitor chemical or enzymatic reactions at the single molecule level. The electrophoretic translocation of DNA across nanopores reconstituted into artificial membranes
20 holds great promise for practical applications such as DNA sequencing, and biomarker recognition. However, translocation of double-stranded or single-stranded DNA through nanopores having internal surface facing negatively charged amino acids are not efficient. In particular, in nanopores having a negative internal surface charge and radii comparable to the Debye length of the solution, the surface potential produced by the electric-double layer (EDL)
25 on the inner nanopore walls overlaps, resulting in a large electrostatic barrier for the entry of DNA into the nanopore. As a consequence, the translocation of DNA across such nanopores has only been observed using large nanopores (*e.g.*, 10 nm) or using small nanopores (*e.g.*, ~3.5 nm) in high ionic strength solutions or under asymmetry salt concentrations.

SUMMARY

30 The present disclosure is based, at least in part, on the unexpected discovery that while certain protein nanopores, for example, a cytolysin A (ClyA) nanopore, has a negatively-charged narrow constriction (or a region which inhibits or reduces efficiency of translocation), successful capture and translocation of a negatively-charged molecule or polymer (*e.g.*, double stranded or
35 single stranded DNA) through such a protein nanopore having a negatively-charged narrow constriction in low ionic strength solutions can be achieved by introducing positive charges, for example, positively-charged amino acids (*e.g.*, arginines), within the luminal surface of the

protein nanopore (*e.g.*, ClyA nanopore) to capture and orient the negatively-charged molecule or polymer (*e.g.*, double stranded or single stranded DNA) within the nanopore. For example, positive charges, *e.g.*, positively-charged amino acids (*e.g.*, arginines) can be introduced within the luminal surface of a protein nanopore having a negatively-charged narrow constriction (*e.g.*, ClyA nanopore) near its opening (*e.g.*, an opening for entry of a negatively-charged molecule or polymer) and within its midsection.

In certain examples, ClyA-AS, an engineered ClyA version selected for its advantageous properties in planar lipid bilayers, were used to create modified ClyA nanopores as described herein. The internal charges of ClyA-AS were rearranged to induce the capture of DNA by the nanopores at physiological ionic strengths. For example, the modified ClyA nanopore comprises a *cis* opening, a mid-section, and a *trans* opening, wherein an internal surface of the *cis* opening comprises a first positively-charged amino acid substitution; an internal surface of the mid-section comprises a second positively-charged amino acid substitution; and the *trans* opening comprises an electronegative constriction. In some instances, the first positively-charged amino acid substitution (*e.g.*, substitution with arginine) may be positioned within the *cis* opening so as to permit capture of a DNA into the modified ClyA nanopore and/or the second positively-charged amino acid substitution (*e.g.*, substitution with arginine) may be positioned within the mid-section so as to permit translocation of the DNA through the modified ClyA nanopore. For example, the first positively-charged amino acid substitution may correspond to a S110R mutation in the amino acid sequence of ClyA-AS and/or the second positively-charged amino acid substitution may correspond to a D64R mutation in the amino acid sequence of ClyA-AS.

Accordingly, one aspect of the present disclosure features a modified ClyA nanopore, for example, that permits capture of a negatively-charged polymer into the modified ClyA nanopore and/or translocation of the negatively-charged polymer through the modified ClyA nanopore.

The modified ClyA nanopore comprises a first opening, a mid-section, a second opening, and a lumen extending from the first opening through the mid-section to the second opening, wherein a luminal surface of the first opening comprises a first positive charge modification (*e.g.*, a first positively-charged amino acid substitution) and a luminal surface of the mid-section comprises a second positive charge modification (*e.g.*, a second positively charged amino acid substitution).

The luminal surface of the second opening defines an electronegative constriction.

In any of the modified ClyA nanopores described herein, the distance within the lumen from the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) to the second positive charge modification (*e.g.*, the second positively charged amino acid substitution) may vary within a range of about 0.5 nm to about 10 nm. In some embodiments, the distance within the lumen from the first positive charge modification (*e.g.*, the

first positively-charged amino acid substitution) to the first opening surface may vary within a range of about 3 nm to about 7 nm.

Any forms of ClyA may be used to produce the modified ClyA nanopore described herein. For example, the amino acid sequences of wild-type ClyA (ClyA-WT) and ClyA-AS, and nucleotide sequences encoding the same are known in the art. Accordingly, in some embodiments, the modified ClyA nanopore may comprise a subunit polypeptide having an amino acid sequence that is at least about 80% (including, *e.g.*, at least about 85%, at least about 90%, at least about 95%, or higher) identical to the amino acid sequence as set forth in SEQ ID NO: 1, which corresponds to the wild-type ClyA. Alternatively, the modified ClyA nanopore may comprise a subunit polypeptide having an amino acid sequence that is at least about 80% (including, *e.g.*, at least about 85%, at least about 90%, at least about 95%, or higher) identical to the amino acid sequence as set forth in SEQ ID NO: 2, which corresponds to ClyA-AS. In some embodiments, the modified ClyA nanopore may comprise up to 15 substitutions compared to the amino acid sequences as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 including the first and second positively-charged amino acid substitutions.

In any of the modified ClyA nanopores described herein, the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) may be positioned within the first opening so as to permit capture of a negatively charged polymer (*e.g.*, but not limited to a deoxyribonucleic acid (DNA) such as double stranded DNA or single-stranded DNA) within a solution exposed to the first opening. For example, substitution with a positive charge (*e.g.*, a positively-charged amino acid) may take place at one of more of the following positions: E106, D114, D121, D122, E129, E85, E78, D268, D267, D265, E258 of SEQ ID NO: 1 or SEQ ID NO: 2.

In any of the modified ClyA nanopores described herein, the second positive charge modification (*e.g.*, the second positively-charged amino acid substitution) may be positioned within the mid-section so as to permit translocation of the negatively charged polymer (*e.g.*, but not limited to a deoxyribonucleic acid (DNA) such as double stranded DNA or single-stranded DNA) through the lumen of the pore. For example, substitution with a positive charge (*e.g.*, a positively-charged amino acid) may take place at one of more of the following positions: D74, D71, D64, E53, E161, D158, E46, E42, D41 of SEQ NO: 1 or SEQ ID NO: 2.

The distance between the first and second positive charge modifications (*e.g.*, the first and second positively-charged substitutions) is preferably from about 0.5nm to about 10 nm. The distance may be between from about 3 nm to about 7nm.

The modified ClyA nanopore can be homo-multimeric (*e.g.*, all subunits within the nanopore are the same) or hetero-multimeric (*e.g.*, at least one subunit is different from others

within the nanopore). The modified ClyA nanopore may comprise any number of subunit polypeptides that are sufficient to form a lumen large enough to permit a target polymer (*e.g.*, polynucleotide) pass through. In some embodiments, the modified ClyA nanopore may comprise 12 subunit polypeptides or more, including, *e.g.*, 13 subunit polypeptides, and 14 subunit polypeptides, wherein at least one or more of the subunit polypeptides comprises the first and second positively-charged amino acid substitutions as described herein.

The first and second positive charge modifications (*e.g.*, the first and second positively-charged amino acid substitutions) may take place in all the subunits of the nanopore.

Accordingly, modified ClyA nanopore subunit polypeptide and polynucleotides comprising nucleotide sequences encoding the modified ClyA nanopore subunit polypeptides are also provided herein. For example, the modified ClyA nanopore subunit polypeptide comprises an amino acid sequence that is at least about 80% (including, *e.g.*, at least about 85%, at least about 90%, at least about 95%, or higher) identical to the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, and wherein the amino acid sequence comprises a first positive charge modification (*e.g.*, a first positively-charged amino acid substitution) at a position within a range of 106-78 of SEQ ID NO: 1 or SEQ ID NO: 2 and a second positive charge modification (*e.g.*, a second positively-charged amino acid substitution) at a position within a range of 41-74 of SEQ ID NO: 1 or SEQ ID NO: 2. In one example, the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) may be located at position 110 of SEQ ID NO: 1 or SEQ ID NO: 2; and/or the second positive charge modification (*e.g.*, the second positively-charged amino acid substitution) may be located at position 64 of SEQ ID NO: 1 or SEQ ID NO: 2. Examples of the first and/or second positively-charged amino acid substitutions include, but are not limited to substitution with one of an arginine, a histidine, and a lysine.

Also within the scope of the present disclosure are compositions, for example, for use in characterizing a target polymer, *e.g.*, a target negative-charged polymer such as a target polynucleotide. The composition comprises any of the modified ClyA nanopores described herein. The composition may further comprise a membrane (*e.g.*, an artificial membrane) in which the modified ClyA nanopore is situated. The composition may further comprise a low ionic strength solution, for example, a salt solution having an ionic strength of about 100 mM to about 300 mM or about 150 mM to about 300 mM. More generally the salt solution may have an ionic strength of about 50mM to about 1M. In some embodiments, the composition may further comprise a polynucleotide binding protein, which can be optionally coupled to the modified ClyA nanopore.

The modified ClyA nanopores and compositions as described herein can be used for various biosensor or analyte detection applications, but not limited to polynucleotide sequencing.

The analyte may be a protein. In one aspect, a method of translocating a DNA at a low ionic strength is described herein. The method comprises (a) providing, in a low ionic strength solution, any one of the modified ClyA nanopores described herein and a membrane (*e.g.*, an artificial membrane), wherein the modified ClyA nanopore is present in the membrane such that the *cis* opening of the modified ClyA nanopore is present in a *cis* side of the low ionic strength solution and the *trans* opening of the modified ClyA nanopore is present in a *trans* side of the low ionic strength solution; (b) providing a DNA in the *cis* side of the low ionic strength solution; and (c) applying an electrical potential across the modified ClyA nanopore so that the DNA is translocated through the modified ClyA nanopore from the *cis* side to the *trans* side. In one example, the low ionic strength solution may be a salt solution (*e.g.*, a sodium chloride solution) having an ionic strength of about 150 mM to about 300 mM. Such a method may be used for characterizing a polynucleotide (*e.g.*, DNA or RNA).

Accordingly, a method of characterizing a target polynucleotide is also provided herein. The method comprises (a) providing, in a low ionic strength solution (*e.g.*, of about 150 mM to about 300 mM), any one of the modified ClyA nanopores described herein and a membrane, wherein the modified ClyA nanopore is present in the membrane; (b) adding in the low ionic strength solution of step (a) the target polynucleotide; and (c) measuring, during application of a potential across the nanopore, ion flow through the modified ClyA nanopore, wherein the ion flow measurements are indicative of one or more characteristics of the target polynucleotide. Non-limiting examples of the characteristics of the target polynucleotides that can be determined using the methods described herein include (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide, (v) whether or not the target polynucleotide is modified, and thereby characterizing the target polynucleotide, and any combinations thereof.

In any of the aspects described herein, the target polynucleotide can be a single-stranded DNA or a double-stranded DNA.

In any of the aspects described herein, the method can further comprise adding a polynucleotide binding protein in the low ionic strength solution such that the polynucleotide binding protein binds to the target polynucleotide and controls the movement of the target polynucleotide through the modified ClyA nanopore.

The details of one or more embodiments of the disclosure are set forth in the description below. Other features or advantages of the present disclosure will be apparent from the following drawings and detailed description of several embodiments, and also from the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Engineering ClyA nanopore for DNA translocation. Panel A) Cross section for ClyA-AS and ClyA-RR nanopores imbedded into a lipid bilayer constructed by homology modeling from the *E. coli* ClyA structure (PDB: 2WCD, 90% sequence identity). The inner pore lumen is shown as surface representation and shaded according to the “*in vacuo*” electrostatics (darker shade for negative regions, and lighter shade for positive regions, Pymol). The amino acid substitution that were tested are indicated in ClyA-AS (left). ClyA-RR pores contain two additional arginine residues per proteomer at positions 110 and 64 (right). Panel B) Current versus voltage relationship for ClyA-AS and ClyA-RR. Panel C) ssDNA (**1a**, 1 μ M) and (Panel D) dsDNA (1, 170 nM) translocation through ClyA-RR nanopores at physiological ionic strength at +70 mV. The bottom current traces show a magnification of the DNA translocation events. The current signal was acquired at 10 kHz applying a 2-kHz low-pass Bessel filter. The buffer was 150 mM NaCl, 15 mM Tris HCl, pH 7.5, and the temperature 22°C.

FIG. 2. DNA rotaxane formation in 150 mM NaCl solutions. Panel A) A dsDNA rotaxane was formed at +50 mV by adding a hybrid dsDNA/ssDNA thread **1a/1c** (1.0 μ M) complexed with neutravidin (1.2 μ M, monomer) to the *cis* compartment. **1a/1c** contained a 31 bases single stranded overhang at the 5' that was used to hybridize with **1d** (1.0 μ M), a biotinylated ssDNA molecule complementary to the ssDNA overhang of **1a/1c**. Thus, a nanopore/DNA rotaxane is formed only if **1a/1c** translocates the nanopore. When DNA occupied the lumen of ClyA the open pore current was reduced at positive applied potentials (IRES+50 = 84 ± 7 , average $\pm$ S.D., N=3) and enhanced at negative applied potentials (IRES-50 = 1.11 ± 0.06 , average $\pm$ S.D., N=3). Panel B) A ssDNA/dsDNA hybrid rotaxane was formed at +50 mV by adding a 5' biotinylated ssDNA thread **2a** (1.0 μ M, black line) complexed with neutravidin (1.2 μ M, monomer) to the *cis* compartment of a ClyA-RR nanopore. A second 5' biotinylated ssDNA molecule **2b** (1.0 μ M) complementary to the 3' end of **2a** and complexed with neutravidin (1.2 μ M, monomer) was added to the *trans* compartment. Upon rotaxane formation, the reversal of the applied potential to -50 mV induced a current enhancement (IRES-50 = 1.16 ± 0.03 , average $\pm$ S.D., N=3), indicating that the hybrid ssDNA/dsDNA is assembled. The right of the current traces show the voltage relationship (IV curve) for free

ClyA-RR and ClyA-RR in a rotaxane configuration. The black and grey lines in FIG. 2, Panels A and B, indicate the DNA configuration of the two rotaxanes. The buffer used was 15 mM Tris HCl, pH 7.5, and the temperature 22°C. The DNA sequences are shown in Table 3.

FIG. 3. Ionic strength dependency of DNA translocation and threading. Panel A)

Debye strength dependency of the frequency of translocation for dsDNA (circles) and ssDNA (triangles). The frequency of dsDNA translocation events fitted well to a linear regression ($R^2=0.98$), while the frequency of ssDNA fitted better to a single exponential ($R^2=0.99$) than a linear regression ($R^2=0.78$). Panel B) Dependency of the residual current of dsDNA (triangles) and Neutravidin:dsDNA complex (circles) blockades on the solution Debye length. The lines represent linear regressions. Panel C) Same as in Panel B but for ssDNA. Panel D) Ionic strength dependency of DNA threading. Under +70 mV applied potential, the initial addition of ssDNA (**1a**, 1 μ M) to the *cis* side of ClyA-RR induced fast current blockades to ClyA-RR open pore current. The subsequent addition of Neutravidin (1.2 μ M, *cis*) induced long lasting current blockades in 150 and 300 mM NaCl solutions, which are most likely due to the threading of ssDNA. This was not observed in 1 M NaCl solution (or higher), where the blockades remained transient. Further addition of the complimentary ssDNA (**1a**, 1 μ M, *cis*) induced permanent blockades at all ionic strengths due to the threading of dsDNA. After each permanent DNA capture event, the open pore was regenerated by manual reversal of the potential to -70mV. Spikes above and below the open pore current level represent capacitive transients following the potential reversal. The electrical recordings were carried out in 15 mM Tris HCl, pH 7.5, at 22°C. Data were by applying a 10-kHz low-pass Bessel filter and using a 20 μ s (50 kHz) sampling rate and are listed in Table 7. At 150 mM NaCl and additional digital 2-kHz low-pass Bessel filter was applied to the current traces.

FIG. 4. Unidirectional DNA translocation through ClyA-RR nanopores. Panel A) In 150 mM NaCl solutions, the addition of 3 μ M of dsDNA 1 to both the *cis* and *trans* sides of a ClyA-RR nanopores induced transient current blockades (grey vertical lines) only under positive applied potentials. Panel B) In 1.0 M NaCl solutions, the DNA blockades are observed under both applied potentials. DNA induced blockades are shown as grey vertical lines. The applied potential was automatically changed from +70 to -70 mV (Panel A) or from +100 to -100 mV (Panel B) in 21 seconds. The electrical recordings were carried out in 15 mM Tris HCl, pH 7.5, at 22°C. Data were recorded by applying a 2-kHz (Panel A) and 10-kHz (Panel B) low-pass Bessel filter and using a 100 μ s (10 kHz, Panel A) and 50 kHz (Panel B) sampling rate.

FIG. 5. Mechanism of dsDNA and ssDNA translocation through ClyA nanopores.

Panel A) dsDNA translocation. (1) dsDNA initially interact with the charges at the *cis* entrance

of the nanopore. (2) dsDNA penetrate inside the nanopore where it interacts with the second engineered charge. Both charges are important to align the DNA for productive translocation through the negatively charged *trans* constriction. (3) The dsDNA can then translocate and then (4) exit the pore. Panel B) (1) The additional charges at the *cis* entrance mediate the efficient capture of the DNA inside the nanopore. (2) ssDNA enters the *cis* lumen most likely as a coiled structure. (3) In order to translocate the *trans* constriction, ssDNA needs to uncoil to then recoil outside the nanopore. (4) DNA exit the nanopore. The DNA molecules and the nanopore are drawn in scale. R_g indicates the gyration radius of ssDNA. Under the experimental conditions, dsDNA is a rigid rod and ssDNA is a coiled structure with a gyration radius of ~6 nm.

FIG. 6. DNA translocation from the *cis* side of ClyA nanopores in 0.15 M NaCl solutions. For each indicated mutant (Panels A-G) it is reported: the IV relationship (voltage ramp from +100 to -100 mV in 21 s and 10 mV voltage steps) and a representative current trace under positive VG applied potential (Table 5) before and after adding 1 μ M of a biotinylated ssDNA (**1a**, Table 3) to the *cis* compartment. A variety of current traces is also shown after the subsequent addition of 1.2 μ M neutravidin (monomer) and 1 μ M of the complementary ssDNA (**1b** Table 1) to the *cis* solution. The electrical recordings were carried out in 0.15 M NaCl, 15 mM Tris-HCl, pH 7.5 at 22°C. Data were recorded by applying a 2-kHz low-pass Bessel filter and using a 100 μ s (10 kHz) sampling rate.

FIG. 7. Ionic strength dependency of ssDNA translocation. Panels A-F show data for different salt concentrations or ionic strengths. (Left side) Representative current trace showing the open pore current of ClyA-RR nanopores before and after adding 1 μ M of a biotinylated ssDNA (**1a**, Table 3) to the *cis* side of the pore under + 70 mV at different NaCl concentrations. The histograms on the right side represent the dwell times (t_{OFF} , left histogram) and inter-event time (t_{ON} , right histogram) of individual ssDNA translocation events. Individual t_{off} and inter-event time t_{on} events were collected individually by using the “single channel search” function in the Clampfit Software (Molecular devices) using a data acquisition threshold of 0.05 ms. The average DNA translocation dwell times t_{OFF} were calculated from single exponential fits from cumulative histograms. The inter-event times t_{ON} were calculated from exponential logarithmic probability fitting from histograms using logarithmic bins (base 10). The electrical recordings were carried out in 15 mM Tris-HCl, pH 7.5 at 22°C. Data were recorded by applying a 10-kHz low-pass Bessel filter and using a 20 μ s (50 kHz) sampling rate. An additional 2-kHz low-pass Bessel filter was used for the data collected at 0.15 M NaCl solutions.

FIG. 8. Ionic strength dependency of dsDNA translocation. Panels A-E show data for

different salt concentrations or ionic strengths. The current traces show the open pore current of ClyA-RR nanopores before (left) and after (right) the addition of 170 nM dsDNA (**1**, Table 3) added to the *cis* side of the pore under + 70 mV and at indicated NaCl concentrations. The histograms on the right side represent the dwell times (t_{OFF} , left histogram) and inter-event time (t_{ON} , right histogram) of individual ssDNA translocation events. Individual t_{OFF} and inter-event time t_{ON} events were collected individually by using the “single channel search” function in the Clampfit Software (Molecular devices) using a data acquisition threshold of 0.05 ms. The average DNA translocation dwell times τ_{off} were calculated from single exponential fits from cumulative histograms. The inter-event times τ_{on} were calculated from exponential logarithmic probability fitting from histograms using logarithmic bins (base 10). The electrical recordings were carried out in 15 mM Tris-HCl, pH 7.5 at 22°C. Data were recorded by applying a 10-kHz low-pass Bessel filter and using a 20 μ s (50 kHz) sampling rate. An additional 2-kHz low-pass Bessel filter was used for the data collected at 0.15 M NaCl solutions.

FIG. 9. Formation of a DNA rotaxane from the *trans* side at 1 M NaCl. Panel A) The dsDNA rotaxane was formed under -70 mV applied potential by adding a hybrid dsDNA/ssDNA thread T1d (**1a** and **1c**, 1.0 μ M, Table 3, shown as a black line above the current trace) complexed with neutravidin (1.2 μ M, monomer) to the *trans* nanopore compartment. A 3' biotinylated ssDNA molecule, **1d** (1.0 μ M, Table 3, corresponding to the grey line above the current trace) complementary to the overhang of T1d was added to the *cis* compartment. Since the nanopore/DNA rotaxane can only formed if T1d translocates through the nanopore to hybridizes with **1**, this experiments proves the translocation of DNA through ClyA from *cis* to *trans*. At -70 mV the blocked pore current of the threaded DNA was 64 ± 2.0 , average $\pm$ S.D., N=3). After rotaxane formation, the reversal of the applied potential to +70 mV showed a blocked pore current ($I_{\text{RES}+70} = 73 \pm 0.5$, average $\pm$ S.D., N=3), indicating that dsDNA occupied the nanopore. Panel B) IV relationship for ClyA-RR and ClyA-RR in a rotaxane configuration.

FIG. 10. Pore engineering for observing the translocation of DNA from the *trans* side in 0.15 M NaCl solutions. For each mutant indicated in Panels A-I, it is reported: the IV relationship (voltage ramp from +100 to -100 mV in 21 s and 10 mV voltage steps) and a representative current trace under positive V_G applied potential before and after adding 1 μ M of a biotinylated ssDNA (**1a**, Table 3) to the *trans* compartment. A variety of current traces are also shown after the subsequent addition of 1.2 μ M neutravidin (monomer) and 1 μ M of the complementary ssDNA (**1b** Table 1) to the *trans* solution. Although ClyA-3R-E7S showed current blockades following the addition of DNA to the *trans* chamber, a rotaxane could not

be formed, suggesting the blockades are not due to the translocation of DNA. The electrical recordings were carried out in 0.15 M NaCl, 15 mM Tris-HCl. pH 7.5 at 22°C. Data were recorded by applying a 2-kHz low-pass Bessel filter and using a 100 μ s (10 kHz) sampling rate.

FIG. 11. Engineering the ClyA nanopore for DNA translocation. Panel A) Cross sections of the ClyA-AS (left) and ClyA-RR (right) nanopores imbedded into a lipid bilayer constructed by homology modeling from the *Escherichia coli* ClyA structure using VMD and NAMD (PDB: 2WCD, 90% sequence identity). The inner pore lumen is shown using the solvent-accessible surface area as calculated by PyMOL (version 1.8 Schrödinger, LLC) and shaded according to the electrostatic potential in a 150 mM NaCl solution as calculated by the adaptive Poisson–Boltzmann solver (APBS). Shaded regions correspond to negative and positive potentials (range -2 to $+2$ kBT/e or -51.4 to $+51.4$ mV). Panel B) Electrostatic potential at the center of ClyA-AS and ClyA-RR nanopores at 150 mM NaCl concentration.

FIG. 12. DNA rotaxane formation in 150 mM NaCl solutions at +50 mV. Panel A) dsDNA rotaxane was formed by adding **1a/1c** (1.0 μ M, black lines) and **1d** (1.0 μ M, grey line) to the *cis* and *trans* compartments, respectively. Neutravidin (NA, 0.3 μ M, tetramer) was also added in both solutions. Panel B) ssDNA/dsDNA hybrid rotaxane was formed by addition of a 5'-biotinylated ssDNA thread **2a** (1.0 μ M, black line) to the *cis* compartment and a 5'-biotinylated ssDNA molecule complementary to the 3' end of **2a** (**2b**, 1.0 μ M, grey line) to the *trans* compartment. NA (0.3 μ M, tetramer) was present on both sides. The graphs on the right-hand side of the current traces show the voltage relationship (I–V curve) for ClyA-RR and ClyA-RR in a rotaxane configuration. Experiments were carried out in a buffer containing 150 mM NaCl and 15 mM Tris-HCl (pH 7.5) at 22 °C. The DNA sequences are shown in Table 3.

FIG. 13. Ionic strength dependence of DNA translocation and threading under +70 mV. Panels A-B) Debye length dependence of the frequency of dsDNA (Panel A) and ssDNA (Panel B) translocation per 1 μ M DNA. The dotted line in (Panel A) depicts the theoretical prediction of translocation frequencies for a diffusion-limited process. The line in (Panel B) is an exponential regression indicating a barrier-limited process.

FIG. 14. Mechanism of dsDNA and ssDNA translocation through ClyA-RR nanopores. Panel A) dsDNA translocation is diffusion-limited. (i) dsDNA, which under the experimental conditions is a rigid rod, is aligned by the electric field lines and enters the nanopore with a defined orientation. (ii) dsDNA penetrates inside the nanopore, where it interacts with the second layer of engineered charges. (iii) dsDNA can then translocate the constriction and (iv) exit the pore. The charges at the *cis* entry of the nanopore aid in the initial capture. Panel B) ssDNA translocation is reaction-limited. (i) ssDNA has a coiled structure with a gyration

radius ($R_g \approx 6$ nm), which is about twice the radius of the nanopore. (ii) ssDNA is not yet in the pore, and it searches for the entry. (iii) One end of ssDNA finds the entry of the *cis* lumen and starts to uncoil. Because there is an entropic energy barrier to enter the nanopore, several attempts can be made before a successful translocation event. (iv) In order to translocate the constriction, ssDNA needs to fully uncoil. (v) DNA exits the nanopore and then recoils. The additional charges at the *cis* entry most likely mediate the efficient capture of the DNA inside the nanopore. The DNA molecules and the nanopore are drawn to scale.

FIG. 15. Ionic strength dependency of DNA threading. ssDNA (**1a**, 1.0 μ M) was first added to the *cis* side of ClyA-RR, then Neutravidin (NA, 0.3 μ M, *cis*), and finally the complementary ssDNA (**1b**, 1 μ M, *cis*). In 150 and 500 mM NaCl solutions the ssDNA:NA complex induced long-lasting current blockades, which are most likely due to the threading of ssDNA. In 1.0 M NaCl solution (or higher) the ssDNA:NA blockades were transient, suggesting that ssDNA could not fully thread the pore. The dsDNA:NA complex induced permanent blockades at all ionic strengths. Spikes above and below the open pore current level represent capacitive transients following the manual potential reversal used to free the nanopore from the DNA. The electrical recordings were carried out in 15 mM Tris-HCl, pH 7.5, at 22 °C.

FIG. 16. Ionic strength dependency of ssDNA translocation through ClyA-RR nanopores. Panels A-F show data for different salt concentrations or ionic strengths. The current traces show the open pore current of ClyA-RR before and after adding 1.0 μ M of a biotinylated ssDNA (**1a**, Table 3) to the *cis* side of the pore under +70 mV at different NaCl concentrations. The histograms on the right side of the traces represent dwell times (left histogram, conventional binning single exponential fit) and inter-event times (right histogram, logarithmic base 10, exponential logarithmic probability fit) of the dsDNA translocation events. The scattered plots represent currents versus dwell times. The electrical recordings were carried out in 15 mM Tris-HCl, pH 7.5 at 22 °C. Data were recorded by applying a 10-kHz low-pass Bessel filter and using a 20 μ s (50 kHz) sampling rate. An additional 2-kHz low-pass Bessel filter was used for the data collected at 0.15 M NaCl solutions.

FIG. 17. Ionic strength dependency of dsDNA translocation through ClyA-RR nanopores. Panels A-E show data for different salt concentrations or ionic strengths. The current traces show the open pore current of ClyA-RR before and after adding 140-170 nM of a biotinylated dsDNA (**1**, Table 3) to the *cis* side of the pore under +70 mV at different NaCl concentrations. The histograms on the right side of the traces represent dwell times (left histogram, conventional binning single exponential fit) and inter-event times (right histogram, logarithmic base 10, exponential logarithmic probability fit) of the dsDNA translocation

events. The scattered plot represents currents versus dwell times. The electrical recordings were carried out in 15 mM Tris-HCl pH 7.5 at 22 °C. Data were recorded by applying a 10-kHz low-pass Bessel filter and using a 50 kHz sampling rate. An additional 2-kHz low-pass Bessel filter was used for the data collected at 0.15 M NaCl solutions.

FIG. 18. Ionic strength dependency of the DNA translocation frequency filtered at 1 kHz. Salt dependency of the event frequencies for (Panel A) dsDNA and (Panel B) ssDNA as determined from current traces filtered using a 1 kHz digital Gaussian filter (Clampfit, Molecular Devices). The lines show linear (Panel A) and exponential (Panel B) regression fits.

FIG. 19. Entropic and electrophoretic forces acting on ssDNA near a nanopore. ssDNA has a coiled shape and is expected to be captured by the pore via a barrier crossing (reaction-limited process). The barrier originates from a repulsive force of entropic origin in the vicinity of the pore which acts on top of the attractive electrophoretic force. The free energies for these two contributions are indicated with thin lines, while the thick line is the sum of the two (Eq. (15)). The top part of the figure shows two characteristic configurations of the ssDNA characterized by reaction coordinates r_a and r_b , respectively. The configuration (b) has a lower entropy and corresponds to a state close to the top of the barrier.

FIG. 20 shows the structure of ClyA and the *cis* section denoted as A, the mid-section, denoted as B and the *trans* section, denoted as C. The negatively charged amino-acids D and E are shown at the left hand side of the figure (along with the polar uncharged amino-acids S and Q). Substitution of one or more of the polar uncharged amino-acid or the negatively charged amino-acids can take place in A, substitution of one or more of the negatively charged amino-acids can take place in B. Region C which contains a number of negatively charged amino-acids can remain as it is, with no substitutions with neutral or positively charged amino-acids.

DETAILED DESCRIPTION OF THE INVENTION

While transmembrane pores (*e.g.*, protein nanopores or solid state nanopores) are useful as sensors to detect or characterize a biopolymer, translocation of a biopolymer, *e.g.*, a polynucleotide through certain nanopores at low ionic strengths (*e.g.*, about 150 mM to about 300 mM) could be challenging. In particular, nanopores having a portion with a negative internal surface charge and radii comparable to the size of a negatively-charged biopolymer (*e.g.*, ~2.2 nm for the B-form of dsDNA and ~ 1 nm for ssDNA) can create a large electrostatic barrier for the entry of the negative-charged biopolymer into the nanopore at low ionic strengths. Accordingly, there is a need to engineer transmembrane nanopores that permit more efficient capture and/or translocation of a negatively-charged biopolymer, *e.g.*, a polynucleotide, across the nanopores, which can be useful for practical applications such as polynucleotide mapping or sequencing.

The present disclosure is based, at least in part, on the unexpected discovery that positive charges can be introduced into the luminal surface of a transmembrane nanopore, for example, a cytolysin A (ClyA), at certain positions to overcome the entropic and electrostatic barriers for DNA translocation through the negatively charged narrow constriction (*e.g.*, with a dimension of about 3.3 nm). For example, it was discovered that introduction of positive changes (*e.g.*, positively-charged amino acids such as arginines) at the wider entry (the *cis* side) and midsection of the ClyA nanopore are sufficient to "grab" and orient the DNA (*e.g.*, double stranded or single stranded) for effective electrophoretic-driven sliding through the narrow and negatively charged *trans* constriction, even in the absence of any modifications to the negatively charged *trans* constriction itself. Further, it was discovered that such modifications permit DNA translocation at low ionic strengths, *e.g.*, as low as 50 mM. In principle the modifications allow the methods of any aspects described herein to be carried out at even lower ionic strengths than 50mM. However lower ionic strengths may give rise to correspondingly lower ionic currents and therefore, in some circumstances, may not be desirable. Without such modifications, translocation of single-stranded or double-stranded DNA through the nanopore was only observed above 2.0 M ionic strength.

Accordingly, in some aspects, the present disclosure provides modified ClyA nanopore subunit polypeptide (*e.g.*, for forming a modified ClyA nanopore) and nanopores comprising the same. The modified ClyA nanopores as described herein can be used for various practical applications such as characterizing a polynucleotide. Accordingly, described herein are also methods and compositions for characterizing a polynucleotide such as a double stranded or single stranded polynucleotide. The methods and compositions described herein provide efficient translocation of doubled stranded or single stranded polynucleotide at physiological ionic strengths (*e.g.*, 50 mM-300 mM) or low ionic strengths (*e.g.*, less than 2 M or less than 1 M).

The modified ClyA nanopores and methods described herein permit unidirectional translocation of a polynucleotide, namely the polynucleotide is unable to enter and transit the nanopore in the *trans* to *cis* direction. This enables for example the filtering of polynucleotide (*e.g.*, DNA) in the *cis* to *trans* direction.

It is also contemplated that other nanostructures having a similar nanopore structure as that of the ClyA nanopore (*e.g.*, a cylindrical lumen with a larger diameter (*e.g.*, 5-7 nm) at the *cis* opening and a negatively charged narrower constriction (*e.g.*, 3-4 nm in diameter) at the *trans* opening) can adopt similar modification strategy to allow DNA translocation in low ionic strength solutions.

Modified ClyA nanopore subunit polypeptides

One aspect of the present disclosure provides modified ClyA nanopore subunit polypeptides. A modified ClyA nanopore subunit polypeptide is a polypeptide whose sequence varies from that of a reference ClyA amino acid sequence. The amino acid sequence of the modified ClyA nanopore subunit polypeptide comprises (i) a *cis* opening-forming amino acid sequence, (ii) a midsection-forming amino acid sequence, and (iii) a *trans* opening-forming amino acid sequence. The *cis* opening-forming amino acid sequence is a portion of the amino acid sequence that forms part of a *cis* opening of a nanopore when the modified ClyA nanopore subunit polypeptide interacts with other subunit polypeptides to form the nanopore in a membrane. The midsection-forming amino acid sequence is a portion of the amino acid sequence that forms part of a mid-section of the nanopore when the modified ClyA nanopore subunit polypeptides interacts with other subunit polypeptides to form the nanopore in a membrane. The *trans* opening-forming amino acid sequence is a portion of the amino acid sequence that forms part of a *trans* opening of a nanopore when the modified ClyA nanopore subunit polypeptide interacts with other subunit polypeptides to form the nanopore in a membrane. Methods to identify portions of the ClyA amino acid sequence that correspond to the *cis* portion, mid-section, and *trans* portion of a ClyA nanopore are known in the art and also described in the Examples. For example, a nanopore, a portion of which is embedded into a membrane can be constructed by homology modeling from a known ClyA structure using VMD, *e.g.*, as described in Humphrey et al., "VMD: Visual Molecular Dynamics" J. Mol. Graphics (1996) 14: 33-38; and NAMD, *e.g.*, as described in Phillips et al., "Scalable Molecular Dynamics with NAMD" J. Comput. Chem. (2005) 26: 1781-1802. See, *e.g.*, FIG. 1A.

As used herein, the term "reference ClyA amino acid sequence" refers to a known amino acid sequence of a ClyA nanopore subunit. Various forms of ClyA nanopore subunits are known in the art, including, *e.g.*, but not limited to ClyA wild-type (ClyA-WT), ClyA-SS, ClyA-CS, and ClyA-AS. See, *e.g.*, Soskine et al. "Tuning the size and properties of ClyA nanopores assisted by directed evolution" J Am Chem Soc. (2013) 135: 13456-13463, which describes different mutations in ClyA-SS, ClyA-CS, and ClyA-AS, relative to ClyA-WT, and methods of making them. Any ClyA amino acid sequences described in WO 2016/166232 and WO 2014/153625 can also be used as a reference ClyA amino acid sequence. In one embodiment, the reference ClyA amino acid sequence is an amino acid sequence of ClyA-WT as set forth in SEQ ID NO: 1. In one embodiment, the reference amino acid is an amino acid sequence of ClyA-AS as set forth in SEQ ID NO: 2, which contains the following mutations: C87A, L99Q, E103G, F166Y, I203V, C285S, K294R, as compared to the amino sequence of ClyA-WT as set forth in SEQ ID NO: 1. In some embodiments, the amino acid sequence of

ClyA-AS can further include H307Y, as compared to the amino acid sequence of ClyA-WT.

In some embodiments, the modified ClyA nanopore subunit polypeptide comprises an amino acid sequence that is at least about 80% (including, *e.g.*, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or higher) identical to a reference ClyA amino acid sequence. Standard methods in the art may be used to determine homology. For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology, for example used on its default settings (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent residues or corresponding sequences (typically on their default settings)), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S.F et al (1990) J Mol Biol 215:403-10. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

The amino acid sequence of the modified ClyA nanopore subunit polypeptide comprises (i) a first positive charge modification (*e.g.*, a first positively-charged amino acid substitution) at a position within the *cis* opening-forming amino acid sequence; and (ii) a second positive charge modification (*e.g.*, a second positively-charged amino acid substitution) at a position within the midsection-forming amino acid sequence. The first and second positive charge modifications (*e.g.*, the first and second positively-charged substitutions) are selected to provide higher frequency of capture and/or translocation of a negatively-charged polymer (*e.g.*, a polynucleotide such as double stranded or single stranded DNA) through the nanopore, as compared to a reference ClyA amino acid sequence.

In one embodiment, the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) may be at position 110 of the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, substitution with a positive charge (*e.g.*, a positively-charged amino acid) may take place at one of more of the following positions: E106, D114, D121, D122, E129, E85, E78, D268, D267, D265, E258 of SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, a ClyA amino acid sequence (*e.g.*, as set forth in SEQ ID NO 1 or 2) may be modified or engineered to include additional amino acids "MI" at its N-terminus.

In one embodiment, the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) may be at position 64 of the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, substitution with a positive charge (*e.g.*, a positively-charged amino acid) may take place at one of more of the following positions: D74, D71, D64, E53, E161, D158, E46, E42, D41 of SEQ NO: 1 or SEQ ID NO: 2.

The term "positively-charged amino acid substitution" as used herein refers to a modification to a reference amino acid that increases the net positive charge, or decreases the net negative charge, of the reference amino acid, *e.g.*, as detected at pH 7.0-8.0 (*e.g.*, at pH 8.0) and at room temperature, *e.g.*, at 20-25°C. For example, a positively-charged amino acid substitution can include, but is not limited to, (i) replacement of a negatively-charged amino acid with a less negatively charged amino acid, neutral amino acid, or positively-charged amino acid, (ii) replacement of a neutral amino acid with a positively-charged amino acid, or (iii) replacement of a positively charged amino acid with a more positively-charged amino acid. In some embodiments, a positively-charged amino acid substitution may include deletion of a negatively-charged amino acid or addition of a positively-charged amino acid. In some embodiments, a positively-charged amino acid substitution may include one or more chemical modifications of one or more negatively charged amino acids which neutralize their negative charge. For instance, the one or more negatively charged amino acids may be reacted with a carbodiimide.

A positively-charged amino acid is an amino acid having an isoelectric point (pI) that is higher than the pH of a solution so that the amino acid in the solution carries a net positive charge. For example, examples of a positively-charged amino acid as detected at pH 7.0-8.0 (*e.g.*, at pH 8.0) and at room temperature, *e.g.*, at 20-25°C, include, but are not limited to arginine (R), histidine (H), and lysine (K). A negatively-charged amino acid is an amino acid having a pI that is lower than the pH of a solution so that the amino acid in the solution carries a net negative charge. Examples of a negatively-charged amino acid as detected at pH 7.0-8.0 (*e.g.*, at pH 8.0) and at room temperature, *e.g.*, at 20-25°C, include, but are not limited to aspartic acid (D), glutamic acid (E), serine (S), glutamine (Q). A neutral amino acid is an amino acid having an isoelectric point (pI) that is same as the pH of a solution so that the amino acid in the solution carries no net charge. The pI values of amino acids are known in the art. By comparing the pI value of an amino acid of interest to the pH of a solution, one of ordinary skill in the art will readily determine whether the amino acid present in the solution is a positively charged amino acid, a neutral amino acid, or a negatively-charged amino acid. As used herein, the term "amino acid" can be an naturally-occurring or synthetic amino acid.

In some embodiments, the first and/or second positively-charged amino acid substitutions, *e.g.*, as detected at pH 7.0-8.0 (*e.g.*, at pH 8.0) and at room temperature, *e.g.*, at 20-25°C, include, but are not limited to substitution of a reference amino acid with one of an arginine, a histidine, and a lysine.

In some embodiments, the first positively-charged amino acid substitution is S110R, wherein position 110 corresponds to amino acid 110 of SEQ ID NO: 1 or SEQ ID NO: 2.

In some embodiments, the second positively-charged amino acid substitution is D64R, wherein position 64 corresponds to amino acid 64 of SEQ ID NO: 1 or SEQ ID NO: 2.

In addition to the first and second positively-charged amino acid substitutions described herein, amino acid substitutions may be made to a reference ClyA amino acid sequence, for example up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 30 substitutions. Conservative substitutions replace amino acids with other amino acids of similar chemical structure, similar chemical properties or similar side-chain volume. The amino acids introduced may have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality or charge to the amino acids they replace. Alternatively, the conservative substitution may introduce another amino acid that is aromatic or aliphatic in the place of a pre-existing aromatic or aliphatic amino acid.

Conservative amino acid changes are well-known in the art and may be selected in accordance with the properties of the 20 main amino acids as defined in Table A below. Where amino acids have similar polarity, this can also be determined by reference to the hydropathy scale for amino acid side chains in Table A.

Table A – Chemical properties of amino acids

Ala	aliphatic, hydrophobic, neutral	Met	hydrophobic, neutral
Cys	polar, hydrophobic, neutral	Asn	polar, hydrophilic, neutral
Asp	polar, hydrophilic, charged (-)	Pro	hydrophobic, neutral
Glu	polar, hydrophilic, charged (-)	Gln	polar, hydrophilic, neutral
Phe	aromatic, hydrophobic, neutral	Arg	polar, hydrophilic, charged (+)
Gly	aliphatic, neutral	Ser	polar, hydrophilic, neutral
His	aromatic, polar, hydrophilic, charged (+)	Thr	polar, hydrophilic, neutral
Ile	aliphatic, hydrophobic, neutral	Val	aliphatic, hydrophobic, neutral
Lys	polar, hydrophilic, charged(+)	Trp	aromatic, hydrophobic, neutral
Leu	aliphatic, hydrophobic, neutral	Tyr	aromatic, polar, hydrophobic

Table B - Hydropathy scale

Side Chain	Hydropathy
Ile	4.5
Val	4.2
Leu	3.8
Phe	2.8
Cys	2.5
Met	1.9
Ala	1.8

	Gly	-0.4
	Thr	-0.7
	Ser	-0.8
	Trp	-0.9
5	Tyr	-1.3
	Pro	-1.6
	His	-3.2
	Glu	-3.5
	Gln	-3.5
10	Asp	-3.5
	Asn	-3.5
	Lys	-3.9
	Arg	-4.5

One or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2 may additionally be deleted from the polypeptides described above. Up to 1, 2, 3, 4, 5, 10, 20 or 30 residues may be deleted, or more.

One or more amino acids may be alternatively or additionally added to the polypeptides described above. An extension may be provided at the amino terminal or carboxy terminal of the amino acid sequence of SEQ ID NO: 1 or 2 or polypeptide variant or fragment thereof. The extension may be quite short, for example from 1 to 10 amino acids in length. Alternatively, the extension may be longer, for example up to 50 or 100 amino acids. A carrier protein may be fused to an amino acid sequence, *e.g.*, an amino acid sequence of a modified ClyA nanopore subunit polypeptide. Other fusion proteins are discussed in more detail below.

Methods for modifying amino acids (*e.g.*, by substitution, addition, or deletion) are well known in the art. For instance, a reference amino acid may be substituted with a target amino acid by replacing the codon for the reference amino acid with a codon for the target amino acid at the relevant position in a polynucleotide encoding the modified ClyA nanopore subunit polypeptide. The polynucleotide can then be expressed as discussed below. If the amino acid is a non-naturally-occurring amino acid, it may be introduced by including synthetic aminoacyl-tRNAs in the IVTT system used to express the modified ClyA nanopore subunit polypeptide. Alternatively, it may be introduced by expressing the modified ClyA nanopore subunit polypeptide in *E. coli* that are auxotrophic for specific amino acids in the presence of synthetic (*i.e.*, non-naturally-occurring) analogues of those specific amino acids. They may also be produced by naked ligation if the modified ClyA nanopore subunit polypeptide is produced using partial peptide synthesis.

In some embodiments, the *trans* opening-forming amino acid sequence of the modified ClyA nanopore subunit polypeptide may carry a net negative charge, *e.g.*, as detected at pH 7.0-8.0 (*e.g.*, at pH 8.0) and room temperature (*e.g.*, at 20-25°C), which is comparable to (*e.g.*, within 10%, within 5%, within 4%, within 3%, within 2%, within 1%, or lower) the net negative

charge of the corresponding *trans* opening-forming portion of a reference ClyA amino acid sequence. For example, in some embodiments, the *trans* opening forming amino acid sequence of the modified ClyA nanopore subunit polypeptide can be at least about 95% or higher (including, *e.g.*, at least about 96%, at least about 97%, at least about 98%, at least about 99% or up to 100%) identical to the corresponding *trans* opening-forming portion of a reference ClyA amino acid sequence, *e.g.*, as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. In one embodiment, the *trans* opening-forming amino acid sequence of the modified ClyA nanopore subunit polypeptide is 100% identical to the corresponding *trans* opening-forming portion of the amino acid sequence as set forth in SEQ ID NO: 2.

The modified ClyA nanopore subunit polypeptides described herein may be used to form a homo-multimeric nanopore or hetero-multimeric nanopore as described herein. Accordingly, in some embodiments, the modified ClyA nanopore subunit polypeptide retains the ability to form a nanopore with other subunit polypeptides. Methods for assessing the ability of modified monomers to form nanopores are well-known in the art. For instance, a modified ClyA nanopore subunit polypeptide may be inserted into an amphiphilic layer along with other appropriate subunits and its ability to oligomerize to form a pore may be determined. Methods are known in the art for inserting subunits into membranes, such as amphiphilic layers. For example, subunits may be suspended in a purified form in a solution containing a triblock copolymer membrane such that it diffuses to the membrane and is inserted by binding to the membrane and assembling into a functional state. Alternatively, subunits may be directly inserted into the membrane using the “pick and place” method described in M.A. Holden, H. Bayley. J. Am. Chem. Soc. 2005, 127, 6502-6503 and International Application No. PCT/GB2006/001057 (published as WO 2006/100484).

The modified ClyA nanopore subunit polypeptides may contain non-specific modifications as long as they do not interfere with nanopore formation. A number of non-specific side chain modifications are known in the art and may be made to the side chains of the amino acids. Such modifications include, for example, reductive alkylation of amino acids by reaction with an aldehyde followed by reduction with NaBH₄, amidination with methylacetimidate or acylation with acetic anhydride.

The modified ClyA nanopore subunit polypeptides can be produced using standard methods known in the art. The modified ClyA nanopore subunit polypeptides may be made synthetically or by recombinant means. For example, the modified ClyA nanopore subunit polypeptides may be synthesized by in vitro translation and transcription (IVTT). Suitable methods for producing pores and modified ClyA nanopore subunit polypeptides are discussed in International Application Nos. PCT/GB09/001690 (published as WO 2010/004273),

PCT/GB09/001679 (published as WO 2010/004265) or PCT/GB10/000133 (published as WO 2010/086603).

The modified ClyA nanopore subunit polypeptides as described herein may be produced using D-amino acids. For instance, the modified ClyA nanopore subunit polypeptides as described herein may comprise a mixture of L-amino acids and D-amino acids. This is conventional in the art for producing such proteins or peptides.

In some embodiments, the modified ClyA nanopore subunit polypeptides may be chemically modified. The modified ClyA nanopore subunit polypeptides can be chemically modified in any way and at any site. For instance, the modified ClyA nanopore subunit polypeptides may be chemically modified by attachment of a dye or a fluorophore. In some embodiments, the modified ClyA nanopore subunit polypeptide may be chemically modified by attachment of a molecule to one or more cysteines (cysteine linkage), attachment of a molecule to one or more lysines, attachment of a molecule to one or more non-natural amino acids, enzyme modification of an epitope or modification of a terminus. Suitable methods for carrying out such modifications are well-known in the art.

In some embodiments, the modified ClyA nanopore subunit polypeptide may be chemically modified with a molecular adaptor that facilitates the interaction between a nanopore comprising the modified ClyA nanopore subunit polypeptide and a target nucleotide or target polynucleotide sequence. The presence of the adaptor improves the host-guest chemistry of the nanopore and the nucleotide or polynucleotide sequence and thereby improves the sequencing ability of pores formed from the modified ClyA nanopore subunit polypeptides. The principles of host-guest chemistry are well-known in the art. The adaptor has an effect on the physical or chemical properties of the nanopore that improves its interaction with the nucleotide or polynucleotide sequence. The adaptor may alter the charge of the barrel or channel of the pore or specifically interact with or bind to the nucleotide or polynucleotide sequence thereby facilitating its interaction with the pore.

In some embodiments, the molecular adaptor may be a cyclic molecule, a cyclodextrin, a species that is capable of hybridization, a DNA binder or interchelator, a peptide or peptide analogue, a synthetic polymer, an aromatic planar molecule, a small positively-charged molecule or a small molecule capable of hydrogen-bonding.

In some embodiments, the molecular adaptor can be covalently attached to the modified ClyA nanopore subunit polypeptide. The adaptor can be covalently attached to the nanopore using any method known in the art. The adaptor is typically attached via chemical linkage. If the molecular adaptor is attached via cysteine linkage, one or more cysteines can be introduced

to the modified ClyA nanopore subunit polypeptide by substitution.

In other embodiment, the modified ClyA nanopore subunit polypeptide may be attached or coupled to a polynucleotide binding protein, *e.g.*, helicases, exonucleases, and polymerases. In some embodiments, the modified ClyA nanopore subunit polypeptide may be attached or
5 coupled to a helicase, *e.g.*, a DNA helicase. Examples of helicases, exonucleases, and polymerases that are suitable for use in nanopore sequencing are known in the art. In some embodiments, the modified ClyA nanopore subunit polypeptide may be attached or coupled to a helicase, *e.g.*, a DNA helicase, a Hel308 helicase (*e.g.*, as described in WO 2013/057495), a RecD helicase (*e.g.*, as described in WO2013/098562), a XPD helicase (*e.g.*, as described in
10 WO201/098561), or a Dda helicase (*e.g.*, as described in WO2015/055981). This forms a modular sequencing system that may be used in the methods of characterizing a target polynucleotide. Polynucleotide binding proteins are discussed below. The translocation speed control may be determined by the type of polynucleotide binding protein and/or amount of fuel (ATP) added to the system. For example, the rate of translocation of the double stranded DNA
15 analyte may be controlled by a double stranded DNA translocase such as FtsK. Depending upon the fuel (ATP) added to the system, the translocation speed of a target polynucleotide can be between about 30 B/s and 1000 B/s.

In some embodiments, the polynucleotide binding protein can be covalently attached to the modified ClyA nanopore subunit polypeptide. The polynucleotide binding protein can be
20 covalently attached to the modified ClyA nanopore subunit polypeptide using any method known in the art. The modified ClyA nanopore subunit polypeptide and the polynucleotide binding protein may be chemically fused or genetically fused. The modified ClyA nanopore subunit polypeptide and the polynucleotide binding protein are genetically fused if the whole construct is expressed from a single polynucleotide sequence. Genetic fusion of a modified
25 ClyA nanopore subunit polypeptide to a polynucleotide binding protein is discussed in International Application No. PCT/GB09/001679 (published as WO 2010/004265).

The modified ClyA nanopore subunit polypeptide may be chemically modified with a molecular adaptor and a polynucleotide binding protein.

Any of the proteins described herein, such as the modified ClyA nanopore subunit
30 polypeptides and nanopores described herein, may be modified to assist their identification or purification, for example by the addition of histidine residues (a his tag), aspartic acid residues (an asp tag), a streptavidin tag, a flag tag, a SUMO tag, a GST tag or a MBP tag, or by the addition of a signal sequence to promote their secretion from a cell where the polypeptide does not naturally contain such a sequence. An alternative to introducing a genetic tag is to

chemically react a tag onto a native or engineered position on the protein. An example of this would be to react a gel-shift reagent to a cysteine engineered on the outside of the protein. This has been demonstrated as a method for separating hemolysin hetero-oligomers (Chem Biol. 1997 Jul;4(7):497-505).

5 Any of the proteins described herein, such as the modified ClyA nanopore subunit polypeptide and nanopores described herein, may be labelled with a detectable label. The detectable label may be any suitable label which allows the protein to be detected. Suitable labels include, but are not limited to, fluorescent molecules, radioisotopes, *e.g.*, 125I, 35S, enzymes, antibodies, antigens, polynucleotides and ligands such as biotin.

10 Any of the proteins described herein, including the modified ClyA nanopore subunit polypeptide described herein, can be produced using standard methods known in the art. Polynucleotide sequences encoding a protein may be derived and replicated using standard methods in the art. Polynucleotide sequences encoding a protein may be expressed in a bacterial host cell using standard techniques in the art. The protein may be produced in a cell by
15 in situ expression of the polypeptide from a recombinant expression vector. The expression vector optionally carries an inducible promoter to control the expression of the polypeptide. These methods are described in Sambrook, J. and Russell, D. (2001). *Molecular Cloning: A Laboratory Manual*, 3rd Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

20 Proteins may be produced in large scale following purification by any protein liquid chromatography system from protein producing organisms or after recombinant expression. Typical protein liquid chromatography systems include FPLC, AKTA systems, the Bio-Cad system, the Bio-Rad BioLogic system and the Gilson HPLC system.

Polynucleotides encoding the modified ClyA nanopore subunit polypeptides

25 Provided herein are also polynucleotide sequences encoding any one of the modified ClyA nanopore subunit polypeptides as described herein.

Polynucleotide sequences may be derived and replicated using standard methods in the art. Chromosomal DNA encoding wild-type ClyA may be extracted from a pore producing organism, such as *Salmonella typhi*. The gene encoding the pore subunit may be amplified
30 using PCR involving specific primers. The amplified sequence may then undergo site-directed mutagenesis. Suitable methods of site-directed mutagenesis are known in the art and include, for example, combine chain reaction. Polynucleotides encoding any one of the modified ClyA nanopore subunit polypeptides can be made using well-known techniques, such as those described in Sambrook, J. and Russell, D. (2001). *Molecular Cloning: A Laboratory Manual*,

3rd Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

The resulting polynucleotide sequence may then be incorporated into a recombinant replicable vector such as a cloning vector. The vector may be used to replicate the polynucleotide in a compatible host cell. Thus polynucleotide sequences may be made by
5 introducing a polynucleotide into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells for cloning of polynucleotides are known in the art.

Another aspect of the disclosure includes a method of producing a modified ClyA
10 nanopore subunit polypeptide or a construct described herein. The method comprises expressing a polynucleotide encoding any embodiment of the modified ClyA nanopore subunit polypeptides in a suitable host cell. The polynucleotide is preferably part of a vector and is preferably operably linked to a promoter.

Modified ClyA nanopores

15 One aspect of the present disclosure features a modified ClyA nanopore, for example, that permits capture of a negatively-charged polymer (*e.g.*, polynucleotide such as DNA or RNA) into the modified ClyA nanopore and/or translocation of the negatively-charged polymer through the modified ClyA nanopore. The modified ClyA nanopore comprises a first opening, a mid-section, a second opening, and a lumen extending from the first opening through the mid-
20 section to the second opening, wherein a luminal surface of the first opening comprises a first positively-charged amino acid substitution and a luminal surface of the mid-section comprises a second positively charged amino acid substitution. The luminal surface of the second opening defines an electronegative constriction. The first positive-charged amino acid substitution and the second charged amino acid substitution are described in detail in the section "Modified ClyA
25 nanopore subunit polypeptide" above.

For illustrative purpose only, FIG. 1 (panel A) shows a modified ClyA nanopore according to one embodiment described herein. The modified ClyA nanopore comprises a first opening 102, a mid-section 104, and a second opening 106. The lumen 108 extends from the first opening 102 through the mid-section 104 to the second opening 106 and has a total length
30 of about 13 nm to about 15 nm. The first opening 102 and the mid-section 104 have a diameter of about 5 nm to about 7 nm. The luminal surface of the second opening 106 defines an electronegative constriction 112, wherein the narrowest cross-section has a diameter of about 3 nm to about 4 nm. The second opening 106 (with a length of about 3 nm to about 5 nm) of the modified ClyA nanopore is inserted into a membrane (*e.g.*, a bilayer) 110 such that a solution in

which the modified ClyA nanopore is present is separated into two sides and the first opening 102 is present in one side of the solution while the electronegative constriction 112 is present in another side of the solution. When a target polymer (*e.g.*, target polynucleotide) is added on the same side as the first opening 102, the first opening 102 is a *cis* opening and the second opening 106 is a *trans* opening.

As used herein, the term "luminal surface" refers to the internal surface of a lumen that is exposed to a solution.

As used interchangeably herein, the term "electronegative constriction" or "negatively-charged constriction" refers to a constriction having a net negative surface charge. For example, the luminal surface of the second opening that defines an electronegative constriction has a net negative surface charge as shown in FIG. 1 (panel A).

In any of the modified ClyA nanopores described herein, the distance within the lumen from the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) to the second positive charge modification (*e.g.*, the second positively charged amino acid substitution) may vary within a range of about 0.5 nm to about 10 nm, or about 3 nm to about 7 nm. In some embodiments, the distance within the lumen from the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) to the second positive charge modification (*e.g.*, the second positively charged amino acid substitution) may be about 1 nm, about 2 nm, about 3 nm, about 4 nm, about 5 nm, about 6 nm, about 7 nm, about 8 nm, or about 9 nm.

Any forms of ClyA may be used to produce the modified ClyA nanopore described herein. For example, as described above, the amino acid sequences of various forms of ClyA, including, *e.g.*, but not limited to wild-type ClyA (ClyA-WT) and ClyA-AS, and nucleotide sequences encoding the same are known in the art. Accordingly, in some embodiments, the modified ClyA nanopore may comprise a subunit polypeptide having an amino acid sequence that is at least about 80% (including, *e.g.*, at least about 85%, at least about 90%, at least about 95%, or higher) identical to a reference ClyA amino acid sequence as described herein. In some embodiments, the modified ClyA nanopore may comprise a subunit polypeptide having an amino acid sequence that is at least about 80% (including, *e.g.*, at least about 85%, at least about 90%, at least about 95%, or higher) identical to the amino acid sequence as set forth in SEQ ID NO: 1, which corresponds to the wild-type ClyA. Alternatively, the modified ClyA nanopore may comprise a subunit polypeptide having an amino acid sequence that is at least about 80% (including, *e.g.*, at least about 85%, at least about 90%, at least about 95%, or higher) identical to the amino acid sequence as set forth in SEQ ID NO: 2, which corresponds to the amino acid

sequence of ClyA-AS. In some embodiments, the modified ClyA nanopore may comprise up to 15 substitutions (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 substitutions) compared to the amino acid sequences as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 including the first and second positive charge modifications (*e.g.*, the first and second positively-charged amino acid substitutions).

In any of the modified ClyA nanopores described herein, the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) may be positioned within the first opening so as to permit capture of a negatively charged polymer (*e.g.*, but not limited to a deoxyribonucleic acid (DNA) such as double stranded DNA or single-stranded DNA) within a solution exposed to the first opening. For example, the first positive charge modification (*e.g.*, the first positively-charged amino acid substitution) may be located at position E106, S110, D114, D121, D122, E129, E85, E78, D268, D267, D265, E258, or combinations thereof in the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2.

In any of the modified ClyA nanopores described herein, the second positive charge modification (*e.g.*, the second positively-charged amino acid substitution) may be positioned within the mid-section so as to permit translocation of the negatively charged polymer (*e.g.*, but not limited to a deoxyribonucleic acid (DNA) such as double stranded DNA or single-stranded DNA) through the lumen of the pore. For example, the second positive charge modification (*e.g.*, the second positively-charged amino acid substitution) may be located at position D74, D71, D64, E53, E161, D158, E46, E42, D41, or combinations thereof in the amino acid sequence as set forth in SEQ NO: 1 or SEQ ID NO: 2.

The modified ClyA nanopore can be homo-multimeric (*e.g.*, all subunits within the nanopore are the same) or hetero-multimeric (*e.g.*, at least one subunit is different from others within the nanopore). The modified ClyA nanopore may comprise any number of subunit polypeptides that are sufficient to form a lumen large enough to permit a target polymer (*e.g.*, polynucleotide) pass through. In some embodiments, the modified ClyA nanopore may comprise 12 subunit polypeptides or more, including, *e.g.*, 13 subunit polypeptides, and 14 subunit polypeptides, wherein at least one or more of the subunit polypeptides comprises the first and second positively-charged amino acid substitutions as described herein.

The modified ClyA nanopores can be used for distinguishing double stranded polynucleotides from single stranded polynucleotides, *e.g.*, based on the dwell time in the nanopore and the current flowing through the pore. In addition, the modified ClyA nanopores can be used for characterizing, such as sequencing, polynucleotide sequences. The modified

ClyA nanopores can also be used to distinguish modified bases, *e.g.*, between methylated and unmethylated nucleotides.

The modified ClyA nanopores described herein provide higher frequency of capture and/or translocation of a polynucleotide through the nanopores in low ionic strength solutions, as compared to a ClyA nanopore without the first and second positively-charged substitutions described herein.

As used herein, the term "low ionic strength solution" refers to a solution with an ionic strength of less than 2 M, including, *e.g.*, less than 1 M, less than 900 mM, less than 800 mM, less than 700 mM, less than 600 mM, less than 500 mM, less than 400 mM, less than 300 mM, less than 200 mM, less than 150 mM, or lower. In some embodiments, a lower ionic strength solution has an ionic strength of at least about 50 mM, at least about 100 mM, at least about 150 mM, at least about 200 mM, at least about 300 mM, at least about 400 mM, at least about 500 mM, at least about 600 mM, at least about 700 mM, at least about 800 mM, at least about 900 mM, at least about 1 M, or higher. Combinations of the above-references ranges are also encompassed. For example, a low ionic strength solution may have an ionic strength of about 100 mM to about 600 mM, or about 150 mM to about 300 mM. Any salt can be used to yield a solution with appropriate ionic strength. In some embodiments, alkaline salt (*e.g.*, but not limited to potassium chloride or sodium chloride) can be used in the low ionic strength solution.

The modified ClyA nanopores can discriminate between different nucleotides under a range of conditions. In particular, the pores can discriminate between nucleotides under conditions that are favorable to the characterizing, such as sequencing, of nucleic acids. The extent to which the modified ClyA nanopores can discriminate between different nucleotides can be controlled by altering the applied potential, the salt concentration, the buffer, the temperature and the presence of additives, such as urea, betaine and DTT. This allows the function of the pores to be fine-tuned, particularly when sequencing. This is discussed in more detail below. The modified ClyA nanopores may also be used to identify polynucleotide polymers from the interaction with one or more monomers rather than on a nucleotide by nucleotide basis.

In some embodiments, modified ClyA nanopores provided herein may be used for characterizing nucleic acid-protein interactions. In some embodiments, the nanopores can be used interrogate protein-nucleic acids using different sensing modes such as, for example, by scanning and mapping the locations of binding sites along a nucleic acid and/or by probing the strength of interactions between a protein and nucleic acid. In some embodiments, native charges of a nucleic acid may be leveraged to apply an electrophoretic force to a nucleic acid-

protein complex. For example, in some embodiments, DNA-protein interactions may be evaluated using voltage-driven threading of single DNA molecules through a protein nanopore. In such embodiments, electrical force applied to an individual DNA protein complex (*e.g.*, a DNA-exonuclease I complex, a DNA-helicase complex, a DNA-clamp complex) may pull the two molecules apart, while at the same time ion current changes may be used to evaluate the dissociation rate of the complex. In some embodiments, modified ClyA nanopores provided herein may be used for detection and characterization of nucleic acid-protein interactions involving nucleic acid and other nucleic acid binding proteins such as transcription factors, enzymes, DNA packaging proteins and others.

The modified ClyA nanopores may be isolated, substantially isolated, purified or substantially purified. The modified ClyA nanopores can be isolated or purified if it is completely free of any other components, such as lipids or other pores. A pore is substantially isolated if it is mixed with carriers or diluents which will not interfere with its intended use. For instance, a pore is substantially isolated or substantially purified if it is present in a form that comprises less than 10%, less than 5%, less than 2% or less than 1% of other components, such as triblock copolymers, lipids or other pores. Alternatively, one or more of the modified ClyA nanopores may be present in a membrane. Suitable membranes are discussed below.

The modified ClyA nanopore may be present as an individual or single pore. Alternatively, the modified ClyA nanopores may be present in a homologous or heterologous population of two or more pores. In some embodiments, the modified ClyA nanopores may be arranged in an array of microwells, wherein each microwell contains at least one nanopore in a membrane.

Homo-multimeric ClyA nanopores

Homo-multimeric nanopores comprising identical modified ClyA nanopore subunit polypeptides are also provided herein. The homo-multimeric nanopore may comprise any embodiment of the modified ClyA nanopore subunit polypeptides described herein. The homo-multimeric nanopore can be used for characterizing, such as sequencing, polynucleotides, and/or detecting the presence or absence of single stranded polynucleotide vs double stranded polynucleotide. The homo-multimeric nanopore described herein may have any of the advantages discussed above.

The homo-multimeric pore may contain any number of modified ClyA nanopore subunit polypeptides. The pore typically comprises at least 10, at least 11, at least 12, at least 13, or at least 14 identical modified ClyA nanopore subunit polypeptides, such as 12, 13, or 14 identical modified ClyA nanopore subunit polypeptides.

Methods for making pores are discussed in more detail below.

Hetero-multimeric ClyA nanopores

Hetero-multimeric nanopores comprising at least one modified ClyA nanopore subunit polypeptides are also provided herein. The hetero-multimeric nanopores can be used for
5 characterizing, such as sequencing, polynucleotides, and/or detecting the presence or absence of single stranded polynucleotide vs double stranded polynucleotide. Hetero-multimeric nanopores can be made using methods known in the art (*e.g.*, Protein Sci. 2002 Jul; 11(7):1813-24).

The hetero-multimeric pore contains sufficient subunit polypeptide to form the pore. The subunit polypeptides may be of any type. The pore typically comprises at least 10, at least
10 11, at least 12, at least 13, or at least 14 subunit polypeptides, such as 12, 13, or 14 subunit polypeptides.

In some embodiments, all of the subunit polypeptides (such as 12, 13, or 14 of the subunit polypeptides) are modified ClyA nanopore subunit polypeptides and at least one of them differs from the others. In some embodiments, the pore comprises 12 or 13 modified
15 ClyA nanopore subunit polypeptides and at least one of them differs from the others. They may all differ from one another.

In some embodiments, at least one of the subunit polypeptides is not a modified ClyA nanopore subunit polypeptide as described herein. In this embodiment, the remaining monomers may be any one of the modified ClyA nanopore subunit polypeptides described
20 herein. Hence, the pore may comprise 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modified ClyA nanopore subunit polypeptide(s). The modified ClyA nanopore subunit polypeptide(s) that form the nanopore can be the same or different.

Methods for making pores are discussed in more detail below.

Polynucleotide characterization

Another aspect of the present disclosure provides a method of characterizing a target
25 polynucleotide. The method comprises: (a) providing, in a low ionic strength solution of about 50 mM to about 1 M, a modified ClyA nanopore according to any embodiment described herein and a membrane, wherein the modified ClyA nanopore is present in the membrane; (b) adding in the low ionic strength solution of step (a) the target polynucleotide; and (c) measuring, during
30 application of a potential across the nanopore, ion flow through the modified ClyA nanopore, wherein the ion flow measurements are indicative of one or more characteristics of the target polynucleotide. In some embodiments, the target polynucleotide is added to the *cis* side of the low ionic strength solution.

In some embodiments, the low ionic strength solution may have an ionic strength of about 50 mM to about 300 mM, or about 150 mM to about 300 mM.

The target polynucleotide may also be called the template polynucleotide or the polynucleotide of interest.

5 *Polynucleotide*

A polynucleotide, such as a nucleic acid, is a macromolecule comprising two or more nucleotides. The polynucleotide or nucleic acid may comprise any combination of any nucleotides. The nucleotides can be naturally occurring or artificial. One or more nucleotides in the polynucleotide can be oxidized or methylated. One or more nucleotides in the
10 polynucleotide may be damaged. For instance, the polynucleotide may comprise a pyrimidine dimer. Such dimers are typically associated with damage by ultraviolet light and are the primary cause of skin melanomas. One or more nucleotides in the polynucleotide may be modified, for instance with a label or a tag. Suitable labels are described below. The polynucleotide may comprise one or more spacers.

15 A nucleotide typically contains a nucleobase, a sugar and at least one phosphate group. The nucleobase and sugar form a nucleoside.

The nucleobase is typically heterocyclic. Nucleobases include, but are not limited to, purines and pyrimidines and more specifically adenine (A), guanine (G), thymine (T), uracil (U) and cytosine (C).

20 The sugar is typically a pentose sugar. Nucleotide sugars include, but are not limited to, ribose and deoxyribose. The sugar is preferably a deoxyribose.

The polynucleotide preferably comprises the following nucleosides: deoxyadenosine (dA), deoxyuridine (dU) and/or thymidine (dT), deoxyguanosine (dG) and deoxycytidine (dC).

The nucleotide is typically a ribonucleotide or deoxyribonucleotide. The nucleotide
25 typically contains a monophosphate, diphosphate or triphosphate. The nucleotide may comprise more than three phosphates, such as 4 or 5 phosphates. Phosphates may be attached on the 5' or 3' side of a nucleotide. Nucleotides include, but are not limited to, adenosine monophosphate (AMP), guanosine monophosphate (GMP), thymidine monophosphate (TMP), uridine monophosphate (UMP), 5-methylcytidine monophosphate, 5-hydroxymethylcytidine
30 monophosphate, cytidine monophosphate (CMP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), deoxyadenosine monophosphate (dAMP), deoxyguanosine monophosphate (dGMP), deoxythymidine monophosphate (dTMP), deoxyuridine monophosphate (dUMP), deoxycytidine monophosphate (dCMP) and

deoxymethylcytidine monophosphate. The nucleotides are preferably selected from AMP, TMP, GMP, CMP, UMP, dAMP, dTMP, dGMP, dCMP and dUMP.

A nucleotide may be abasic (i.e., lack a nucleobase). A nucleotide may also lack a nucleobase and a sugar.

5 The nucleotides in the polynucleotide may be attached to each other in any manner. The nucleotides are typically attached by their sugar and phosphate groups as in nucleic acids. The nucleotides may be connected via their nucleobases as in pyrimidine dimers.

The polynucleotide may be single stranded or double stranded. At least a portion of the polynucleotide is preferably double stranded.

10 The polynucleotide can be a nucleic acid, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The polynucleotide can comprise one strand of RNA hybridized to one strand of DNA. The polynucleotide may be any synthetic nucleic acid known in the art, such as peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), locked nucleic acid (LNA) or other synthetic polymers with nucleotide side chains. The PNA backbone
15 is composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. The GNA backbone is composed of repeating glycol units linked by phosphodiester bonds. The TNA backbone is composed of repeating threose sugars linked together by phosphodiester bonds. LNA is formed from ribonucleotides as discussed above having an extra bridge connecting the 2' oxygen and 4' carbon in the ribose moiety.

20 The polynucleotide is most preferably ribonucleic nucleic acid (RNA) or deoxyribonucleic acid (DNA).

The polynucleotide can be any length. For example, the polynucleotide can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400 or at least 500 nucleotides or nucleotide pairs in length. The polynucleotide can be 1000 or more
25 nucleotides or nucleotide pairs, 5000 or more nucleotides or nucleotide pairs in length or 100000 or more nucleotides or nucleotide pairs in length.

Any number of polynucleotides can be investigated. For instance, the method described herein may concern characterizing 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 100 or more polynucleotides. If two or more polynucleotides are characterized, they may be different
30 polynucleotides or two instances of the same polynucleotide.

The polynucleotide can be naturally occurring or artificial. For instance, the method may be used to verify the sequence of a manufactured oligonucleotide. The method is typically carried out in vitro.

The polynucleotide may comprise an attached species such as a protein or analyte. The polynucleotide may comprise a hybridized probe.

Sample

Each analyte is typically present in any suitable sample. The method can be carried out on two or more samples that are known to contain or suspected to contain the analytes. Alternatively, the method may be carried out on two or more samples to confirm the identity of two or more analytes whose presence in the samples is known or expected. In some embodiments, the method may be carried out on samples to distinguish double stranded polynucleotides from single-stranded polynucleotides.

The first sample and/or second sample may be a biological sample. The methods described herein may be carried out in vitro using at least one sample obtained from or extracted from any organism or microorganism. The first sample and/or second sample may be a non-biological sample. The non-biological sample can be a fluid sample. Examples of non-biological samples include surgical fluids, water such as drinking water, sea water or river water, and reagents for laboratory tests.

The first sample and/or second sample is typically processed prior to being used in the methods described herein, for example by centrifugation or by passage through a membrane that filters out unwanted molecules or cells, such as red blood cells. The first sample and/or second sample may be measured immediately upon being taken. The first sample and/or second sample may also be typically stored prior to assay, preferably below -70°C.

Characterization

The method may involve measuring two, three, four or five or more characteristics of the polynucleotide. The one or more characteristics are preferably selected from (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide and (v) whether or not the polynucleotide is modified. Any combination of (i) to (v) may be measured in accordance with the methods described herein, such as {i}, {ii}, {iii}, {iv}, {v}, {i,ii}, {i,iii}, {i,iv}, {i,v}, {ii,iii}, {ii,iv}, {ii,v}, {iii,iv}, {iii,v}, {iv,v}, {i,ii,iii}, {i,ii,iv}, {i,ii,v}, {i,iii,iv}, {i,iii,v}, {i,iv,v}, {ii,iii,iv}, {ii,iii,v}, {ii,iv,v}, {iii,iv,v}, {i,ii,iii,iv}, {i,ii,iii,v}, {i,ii,iv,v}, {i,iii,iv,v}, {ii,iii,iv,v} or {i,ii,iii,iv,v}. Different combinations of (i) to (v) may be measured for the first polynucleotide compared with the second polynucleotide, including any of those combinations listed above.

For (i), the length of the polynucleotide may be measured for example by determining

the number of interactions between the polynucleotide and the pore or the duration of interaction between the polynucleotide and the pore.

For (ii), the identity of the polynucleotide may be measured in a number of ways. The identity of the polynucleotide may be measured in conjunction with measurement of the sequence of the polynucleotide or without measurement of the sequence of the polynucleotide. The former is straightforward; the polynucleotide is sequenced and thereby identified. The latter may be done in several ways. For instance, the presence of a particular motif in the polynucleotide may be measured (without measuring the remaining sequence of the polynucleotide). Alternatively, the measurement of a particular electrical and/or optical signal in the method may identify the polynucleotide as coming from a particular source.

For (iii), the sequence of the polynucleotide can be determined as described previously. Suitable sequencing methods, particularly those using electrical measurements, are described in Stoddart D et al., *Proc Natl Acad Sci*, 12;106(19):7702-7, Lieberman KR et al, *J Am Chem Soc*. 2010;132(50):17961-72, and International Application WO 2000/28312.

For (iv), the secondary structure may be measured in a variety of ways. For instance, if the method involves an electrical measurement, the secondary structure may be measured using a change in dwell time or a change in current flowing through the pore. This allows regions of single-stranded and double-stranded polynucleotide to be distinguished.

For (v), the presence or absence of any modification may be measured. The method preferably comprises determining whether or not the polynucleotide is modified by methylation, by oxidation, by damage, with one or more proteins or with one or more labels, tags or spacers. Specific modifications will result in specific interactions with the pore which can be measured using the methods described below. For instance, methylcytosine may be distinguished from cytosine on the basis of the current flowing through the pore during its interaction with each nucleotide.

The target polynucleotide is contacted with any one of the modified ClyA nanopores described herein. The pore is typically present in a membrane. Suitable membranes are discussed below. The method may be carried out using any apparatus that is suitable for investigating a membrane/pore system in which a pore is present in a membrane. The method may be carried out using any apparatus that is suitable for transmembrane pore sensing. For example, the apparatus comprises a chamber comprising an aqueous solution and a barrier that separates the chamber into two sections. The barrier typically has an aperture in which the membrane containing the pore is formed. Alternatively the barrier forms the membrane in which the pore is present.

The method may be carried out using the apparatus described in International Application No. PCT/GB08/000562 (WO 2008/102120).

A variety of different types of measurements may be made. This includes without limitation: electrical measurements and optical measurements. Possible electrical measurements include: current measurements, impedance measurements, tunneling measurements (Ivanov AP et al., Nano Lett. 2011 Jan 12;11(1):279-85), and FET measurements (International Application WO 2005/124888). Optical measurements may be combined with electrical measurements (Soni GV et al., Rev Sci Instrum. 2010 Jan;81(1):014301). The measurement may be a transmembrane current measurement such as measurement of ionic current flowing through the pore. Alternatively the measurement may be a fluorescence measurement indicative of ion flow through the channel such as disclosed by Heron et al, J. Am. Chem. Soc., 2009, 131 (5), 1652-1653 or measurement of a voltage across the membrane using a FET.

Electrical measurements may be made using standard single channel recording equipment as describe in Stoddart D et al., Proc Natl Acad Sci, 12;106(19):7702-7, Lieberman KR et al, J Am Chem Soc. 2010;132(50):17961-72, and International Application WO 2000/28312. Alternatively, electrical measurements may be made using a multi-channel system, for example as described in International Application WO 2009/077734 and International Application WO 2011/067559.

The method can be carried out with a potential applied across the membrane. The applied potential may be a voltage potential. Alternatively, the applied potential may be a chemical potential. An example of this is using a salt gradient across a membrane, such as an amphiphilic layer. A salt gradient is disclosed in Holden et al., J Am Chem Soc. 2007 Jul 11; 129(27):8650-5. In some instances, the current passing through the pore as a polynucleotide moves with respect to the pore is used to estimate or determine the sequence of the polynucleotide. This may be described as strand sequencing.

The method may involve measuring the current passing through the pore as the polynucleotide moves with respect to the pore. Therefore the apparatus used in the method may also comprise an electrical circuit capable of applying a potential and measuring an electrical signal across the membrane and pore. The methods may be carried out using a patch clamp or a voltage clamp. The methods preferably involve the use of a voltage clamp.

The method may involve the measuring of a current passing through the pore as the polynucleotide moves with respect to the pore. Suitable conditions for measuring ionic currents through transmembrane protein pores are known in the art and disclosed in the Example. The

method is typically carried out with a voltage applied across the membrane and pore. The voltage used is typically from +5 V to -5 V, such as from +4 V to -4 V, +3 V to -3 V or +2 V to -2 V. The voltage used is typically from -600 mV to +600mV or -400 mV to +400 mV. The voltage used is preferably in a range having a lower limit selected from -400 mV, -300 mV, -200 mV, -150 mV, -100 mV, -50 mV, -20mV and 0 mV and an upper limit independently selected from +10 mV, + 20 mV, +50 mV, +100 mV, +150 mV, +200 mV, +300 mV and +400 mV. The voltage used is more preferably in the range 100 mV to 240 mV and most preferably in the range of 120 mV to 220 mV. It is possible to increase discrimination between different nucleotides by a pore by using an increased applied potential.

The method is typically carried out in the presence of any charge carriers, such as metal salts, for example alkali metal salt, halide salts, for example chloride salts, such as alkali metal chloride salt. Charge carriers may include ionic liquids or organic salts, for example tetramethyl ammonium chloride, trimethylphenyl ammonium chloride, phenyltrimethyl ammonium chloride, or 1-ethyl-3-methyl imidazolium chloride. In the exemplary apparatus discussed above, the salt is present in the aqueous solution in the chamber. Potassium chloride (KCl), sodium chloride (NaCl), caesium chloride (CsCl) or a mixture of potassium ferrocyanide and potassium ferricyanide is typically used. KCl, NaCl and a mixture of potassium ferrocyanide and potassium ferricyanide are preferred. The charge carriers may be asymmetric across the membrane. For instance, the type and/or concentration of the charge carriers may be different on each side of the membrane.

The salt concentration may be at saturation. The salt concentration may be 3 M or lower and is typically from 0.1 to 2.5 M, from 0.3 to 1.9 M, from 0.5 to 1.8 M, from 0.7 to 1.7 M, from 0.9 to 1.6 M or from 1 M to 1.4 M. The salt concentration is preferably from 150 mM to 1 M. The method is preferably carried out using a salt concentration of at least 0.3 M, such as at least 0.4 M, at least 0.5 M, at least 0.6 M, at least 0.8 M, at least 1.0 M, at least 1.5 M, at least 2.0 M, at least 2.5 M or at least 3.0 M. High salt concentrations provide a high signal to noise ratio and allow for currents indicative of the presence of a nucleotide to be identified against the background of normal current fluctuations. While the modified ClyA nanopores described herein can be used to characterize a polynucleotide at high salt solution, the modified ClyA nanopores can permit efficient capture and/or translocation of a polynucleotide (*e.g.*, double stranded DNA or single stranded DNA) through the nanopore even in low ionic strength solutions as described above.

The method is typically carried out in the presence of a buffer. In the exemplary apparatus discussed above, the buffer is present in the aqueous solution in the chamber. Any buffer may be used in the methods described herein. Typically, the buffer is phosphate buffer.

Other suitable buffers are HEPES and Tris-HCl buffer. The methods are typically carried out at a pH of from 4.0 to 12.0, from 4.5 to 10.0, from 5.0 to 9.0, from 5.5 to 8.8, from 6.0 to 8.7 or from 7.0 to 8.8 or 7.5 to 8.5. The pH used is preferably about 7.5 or 8.0.

The method may be carried out at from 0 °C to 100 °C, from 15 °C to 95 °C, from 16 °C to 90 °C, from 17 °C to 85 °C, from 18 °C to 80 °C, 19 °C to 70 °C, or from 20 °C to 60 °C. The methods are typically carried out at room temperature. The methods are optionally carried out at a temperature that supports enzyme function, such as about 37 °C.

Polynucleotide binding protein

In some embodiments, the method for characterizing a target polynucleotide may include adding a polynucleotide binding protein in the low ionic strength solution such that the polynucleotide binding protein binds to the target polynucleotide and controls the movement of the target polynucleotide through the modified ClyA nanopore.

The polynucleotide binding protein may be any protein that is capable of binding to the polynucleotide and controlling its movement through the pore. Examples of the polynucleotide binding proteins include, but are not limited to helicases, polymerases, exonucleases, DNA clamps, etc. The polynucleotide may be contacted with the polynucleotide binding protein and the pore in any order. It is preferred that, when the polynucleotide is contacted with the polynucleotide binding protein, such as a helicase, and the pore, the polynucleotide firstly forms a complex with the protein. When the voltage is applied across the pore, the polynucleotide/protein complex then forms a complex with the pore and controls the movement of the polynucleotide through the pore.

Any steps in the method using a polynucleotide binding protein are typically carried out in the presence of free nucleotides or free nucleotide analogues and an enzyme cofactor that facilitates the action of the polynucleotide binding protein.

Helicase(s) and molecular brake(s)

In one embodiment, the method comprises:

- (a) providing the polynucleotide with one or more helicases and one or more molecular brakes attached to the polynucleotide;
- (b) adding the polynucleotide in the low ionic strength solution that comprises a modified ClyA nanopore present in a membrane, and applying a potential across the pore such that the one or more helicases and the one or more molecular brakes are brought together and both control the movement of the polynucleotide through the pore;

(c) measuring, during application of a potential across the nanopore, ion flow through the modified ClyA nanopore, as the polynucleotide moves with respect to the pore wherein the ion flow measurements are indicative of one or more characteristics of the polynucleotide and thereby characterizing the polynucleotide. This type of method is discussed in detail in

5 International Application No.PCT/GB2014/052737.

Membrane

The modified ClyA nanopores described herein may be present in a membrane. In the method of characterizing a polynucleotide, the polynucleotide is typically contacted with a modified ClyA nanopore in a membrane. Any membrane may be used. Suitable membranes
10 are well-known in the art. The membrane is preferably an amphiphilic layer. An amphiphilic layer is a layer formed from amphiphilic molecules, such as phospholipids, which have both hydrophilic and lipophilic properties. The amphiphilic molecules may be synthetic or naturally occurring. Non-naturally occurring amphiphiles and amphiphiles which form a monolayer are known in the art and include, for example, block copolymers (Gonzalez-Perez et al., Langmuir,
15 2009, 25, 10447-10450). Block copolymers are polymeric materials in which two or more monomer sub-units that are polymerized together to create a single polymer chain. Block copolymers typically have properties that are contributed by each monomer sub-unit. However, a block copolymer may have unique properties that polymers formed from the individual sub-units do not possess. Block copolymers can be engineered such that one of the monomer sub-units is hydrophobic or lipophilic, whilst the other sub-unit(s) are hydrophilic whilst in aqueous
20 media. In this case, the block copolymer may possess amphiphilic properties and may form a structure that mimics a biological membrane. The block copolymer may be a diblock (consisting of two monomer sub-units), but may also be constructed from more than two monomer sub-units to form more complex arrangements that behave as amphiphiles. The
25 copolymer may be a triblock, tetrablock or pentablock copolymer. The membrane is preferably a triblock copolymer membrane.

Archaeobacterial bipolar tetraether lipids are naturally occurring lipids that are constructed such that the lipid forms a monolayer membrane. These lipids are generally found in extremophiles that survive in harsh biological environments, thermophiles, halophiles and
30 acidophiles. Their stability is believed to derive from the fused nature of the final bilayer. It is straightforward to construct block copolymer materials that mimic these biological entities by creating a triblock polymer that has the general motif hydrophilic-hydrophobic-hydrophilic. This material may form monomeric membranes that behave similarly to lipid bilayers and encompass a range of phase behaviors from vesicles through to laminar membranes.
35 Membranes formed from these triblock copolymers hold several advantages over biological

lipid membranes. Because the triblock copolymer is synthesized, the exact construction can be carefully controlled to provide the correct chain lengths and properties to form membranes and to interact with pores and other proteins.

Block copolymers may also be constructed from sub-units that are not classed as lipid sub-materials; for example a hydrophobic polymer may be made from siloxane or other non-hydrocarbon based monomers. The hydrophilic sub-section of block copolymer can also possess low protein binding properties, which allows the creation of a membrane that is highly resistant when exposed to raw biological samples. This head group unit may also be derived from non-classical lipid head-groups.

Triblock copolymer membranes also have increased mechanical and environmental stability compared with biological lipid membranes, for example a much higher operational temperature or pH range. The synthetic nature of the block copolymers provides a platform to customize polymer based membranes for a wide range of applications.

The membrane is most preferably one of the membranes disclosed in International Application No. PCT/GB2013/052766 or PCT/GB2013/052767.

The amphiphilic molecules may be chemically-modified or functionalized to facilitate coupling of the polynucleotide.

The amphiphilic layer may be a monolayer or a bilayer. The amphiphilic layer is typically planar. The amphiphilic layer may be curved. The amphiphilic layer may be supported.

Amphiphilic membranes are typically naturally mobile, essentially acting as two dimensional fluids with lipid diffusion rates of approximately 10^{-8} cm s⁻¹. This means that the pore and coupled polynucleotide can typically move within an amphiphilic membrane.

The membrane may be a lipid bilayer. Lipid bilayers are models of cell membranes and serve as excellent platforms for a range of experimental studies. For example, lipid bilayers can be used for in vitro investigation of membrane proteins by single-channel recording.

Alternatively, lipid bilayers can be used as biosensors to detect the presence of a range of substances. The lipid bilayer may be any lipid bilayer. Suitable lipid bilayers include, but are not limited to, a planar lipid bilayer, a supported bilayer or a liposome. The lipid bilayer is preferably a planar lipid bilayer. Suitable lipid bilayers are disclosed in International Application No. PCT/GB08/000563 (published as WO 2008/102121), International Application No. PCT/GB08/004127 (published as WO 2009/077734) and International Application No. PCT/GB2006/001057 (published as WO 2006/100484).

In some embodiments, the polynucleotide can be coupled to the membrane comprising any one of the modified ClyA nanopores described herein. The method may comprise coupling the polynucleotide to the membrane comprising any one of the modified ClyA nanopores described herein. The polynucleotide is preferably coupled to the membrane using one or more anchors. The polynucleotide may be coupled to the membrane using any known method.

Double stranded polynucleotide sequencing

In some embodiments, the polynucleotide may be double stranded. If the polynucleotide is double stranded, the method may further comprises before the contacting step ligating a hairpin adaptor to one end of the polynucleotide. The two strands of the polynucleotide may then be separated as or before the polynucleotide is contacted or interacted with a modified ClyA nanopore as described herein. The two strands may be separated as the polynucleotide movement through the pore is controlled by a polynucleotide binding protein, such as a helicase, or molecular brake. This is described in International Application No. PCT/GB2012/051786 (published as WO 2013/014451). Linking and interrogating both strands on a double stranded construct in this way increases the efficiency and accuracy of characterization.

Round the corner sequencing

In a preferred embodiment, a target double stranded polynucleotide is provided with a hairpin loop adaptor at one end and the method comprises contacting the polynucleotide with any one of the modified ClyA nanopores described herein such that both strands of the polynucleotide move through the pore and taking one or more measurements as the both strands of the polynucleotide move with respect to the pore wherein the measurements are indicative of one or more characteristics of the strands of the polynucleotide and thereby characterizing the target double stranded polynucleotide. Any of the embodiments discussed above equally apply to this embodiment.

Leader sequence

Before the contacting step, the method preferably comprises attaching to the polynucleotide a leader sequence which preferentially threads into the pore. The leader sequence facilitates any of the methods described herein. The leader sequence is designed to preferentially thread into any one of the modified ClyA nanopores described herein and thereby facilitate the movement of polynucleotide through the nanopore. The leader sequence can also be used to link the polynucleotide to the one or more anchors as discussed above.

Modified polynucleotides

Before characterization, a target polynucleotide may be modified by contacting the polynucleotide with a polymerase and a population of free nucleotides under conditions in which the polymerase forms a modified polynucleotide using the target polynucleotide as a template, wherein the polymerase replaces one or more of the nucleotide species in the target polynucleotide with a different nucleotide species when forming the modified polynucleotide. The modified polynucleotide may then be provided with one or more helicases attached to the polynucleotide and one or more molecular brakes attached to the polynucleotide. This type of modification is described in International Application No. PCT/GB2015/050483. Any of the polymerases discussed herein may be used.

The template polynucleotide is contacted with the polymerase under conditions in which the polymerase forms a modified polynucleotide using the template polynucleotide as a template. Such conditions are known in the art. For instance, the polynucleotide is typically contacted with the polymerase in commercially available polymerase buffer, such as buffer from New England Biolabs®. A primer or a 3' hairpin is typically used as the nucleation point for polymerase extension.

Characterization, such as sequencing, of a polynucleotide using a transmembrane pore typically involves analyzing polymer units made up of k nucleotides where k is a positive integer (i.e., 'k-mers'). This is discussed in International Application No. PCT/GB2012/052343 (published as WO 2013/041878). While it is desirable to have clear separation between current measurements for different k -mers, it is common for some of these measurements to overlap. Especially with high numbers of polymer units in the k -mer, i.e., high values of k , it can become difficult to resolve the measurements produced by different k -mers, to the detriment of deriving information about the polynucleotide, for example an estimate of the underlying sequence of the polynucleotide.

By replacing one or more nucleotide species in the target polynucleotide with different nucleotide species in the modified polynucleotide, the modified polynucleotide contains k -mers which differ from those in the target polynucleotide. The different k -mers in the modified polynucleotide are capable of producing different current measurements from the k -mers in the target polynucleotide and so the modified polynucleotide provides different information from the target polynucleotide. The additional information from the modified polynucleotide can make it easier to characterize the target polynucleotide. In some instances, the modified polynucleotide itself may be easier to characterize. For instance, the modified polynucleotide may be designed to include k -mers with an increased separation or a clear separation between their current measurements or k -mers which have a decreased noise.

The polymerase preferably replaces two or more of the nucleotide species in the target polynucleotide with different nucleotide species when forming the modified polynucleotide. The polymerase may replace each of the two or more nucleotide species in the target polynucleotide with a distinct nucleotide species. The polymerase may replace each of the two or more nucleotide species in the target polynucleotide with the same nucleotide species.

If the target polynucleotide is DNA, the different nucleotide species in the modified typically comprises a nucleobase which differs from adenine, guanine, thymine, cytosine or methylcytosine and/or comprises a nucleoside which differs from deoxyadenosine, deoxyguanosine, thymidine, deoxycytidine or deoxymethylcytidine. If the target polynucleotide is RNA, the different nucleotide species in the modified polynucleotide typically comprises a nucleobase which differs from adenine, guanine, uracil, cytosine or methylcytosine and/or comprises a nucleoside which differs from adenosine, guanosine, uridine, cytidine or methylcytidine. The different nucleotide species may be any of the universal nucleotides discussed above.

The polymerase may replace the one or more nucleotide species with a different nucleotide species which comprises a chemical group or atom absent from the one or more nucleotide species. The chemical group may be a propynyl group, a thio group, an oxo group, a methyl group, a hydroxymethyl group, a formyl group, a carboxy group, a carbonyl group, a benzyl group, a propargyl group or a propargylamine group.

The polymerase may replace the one or more nucleotide species with a different nucleotide species which lacks a chemical group or atom present in the one or more nucleotide species. The polymerase may replace the one or more of the nucleotide species with a different nucleotide species having an altered electronegativity. The different nucleotide species having an altered electronegativity preferably comprises a halogen atom.

The method preferably further comprises selectively removing the nucleobases from the one or more different nucleotides species in the modified polynucleotide.

Other characterization method

In another embodiment, a polynucleotide is characterized by detecting labelled species that are released as a polymerase incorporates nucleotides into the polynucleotide. The polymerase uses the polynucleotide as a template. Each labelled species is specific for each nucleotide. The polynucleotide is contacted with a modified ClyA nanopore described herein, a polymerase and labelled nucleotides such that phosphate labelled species are sequentially released when nucleotides are added to the polynucleotide(s) by the polymerase, wherein the phosphate species contain a label specific for each nucleotide. The polymerase may be any of

those discussed above. The phosphate labelled species are detected using the pore and thereby characterizing the polynucleotide. This type of method is disclosed in European Application No. 13187149.3 (published as EP 2682460). Any of the embodiments discussed above equally apply to this method.

5 ***Kits***

Another aspect of the present disclosure also provides a kit for characterizing a target polynucleotide. The kit comprises any one of the modified ClyA nanopores described herein and the components of a membrane. The membrane is preferably formed from the components. The pore is preferably present in the membrane. The kit may comprise components of any of
10 the membranes disclosed above, such as an amphiphilic layer or a triblock copolymer membrane.

The kit may further comprise a polynucleotide binding protein.

The kit may further comprise one or more anchors for coupling the polynucleotide to the membrane.

15 The kit may additionally comprise one or more other reagents or instruments which enable any of the embodiments mentioned above to be carried out. Such reagents or instruments include one or more of the following: suitable buffer(s) (aqueous solutions), means to obtain a sample from a subject (such as a vessel or an instrument comprising a needle), means to amplify and/or express polynucleotides or voltage or patch clamp apparatus. Reagents
20 may be present in the kit in a dry state such that a fluid sample resuspends the reagents. The kit may also, optionally, comprise instructions to enable the kit to be used in any one of the methods described herein or details regarding for which organism the method may be used.

Apparatus

Another aspect described herein also provides an apparatus for characterizing a target
25 polynucleotide. The apparatus comprises a plurality of modified ClyA nanopores as described herein and a plurality of membranes. In some embodiments, the plurality of the modified ClyA nanopores are present in the plurality of membranes. In some embodiments, the numbers of modified ClyA nanopores and membranes are equal. In one embodiment, a single modified ClyA nanopore is present in each membrane.

30 The apparatus can further comprises instructions for carrying out any of the methods as described herein. The apparatus may be any conventional apparatus for polynucleotide analysis, such as an array or a chip. Any of the embodiments discussed above with reference to the methods, *e.g.*, for characterizing a target polynucleotide, are equally applicable to the

apparatus described herein. The apparatus may further comprise any of the features present in the kit described herein.

In some embodiments, the apparatus is set up to carry out any of the methods described herein, *e.g.*, for characterizing a target polynucleotide.

5 In one embodiment, the apparatus comprises: (a) a sensor device that is capable of supporting the plurality of modified ClyA nanopores and membranes and that is operable to perform polynucleotide characterization using the nanopores and membranes; and (b) at least one port for delivery of material for performing the characterization.

10 Alternatively, the apparatus may comprise: (a) a sensor device that is capable of supporting the plurality of modified ClyA nanopores and membranes and that is operable to perform polynucleotide characterization using the nanopores and membranes; and (b) at least one reservoir for holding material for performing the characterization.

15 In another embodiment, the apparatus may comprise: (a) a sensor device that is capable of supporting the membrane and plurality of modified ClyA nanopores and membranes and that is operable to perform polynucleotide characterizing using the pores and membranes; (b) at least one reservoir for holding material for performing the characterizing; (c) a fluidics system configured to controllably supply material from the at least one reservoir to the sensor device; and (d) one or more containers for receiving respective samples, the fluidics system being configured to supply the samples selectively from one or more containers to the sensor device.

20 The apparatus may be any of those described in International Application No. No. PCT/GB08/004127 (published as WO 2009/077734), PCT/GB10/000789 (published as WO 2010/122293), International Application No. PCT/GB10/002206 (published as WO 2011/067559) or International Application No. PCT/US99/25679 (published as WO 00/28312).

25 Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present disclosure to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference for the purposes or subject matter referenced herein.

30

EXAMPLES

Example 1. Precise Nanoscale Engineering of Nanopores to Enable DNA Translocation at

Physiological Ionic Strengths

Many important processes in biology involve the translocation of a biopolymer through nanometer-scale pores, such as nucleic acid transport across nuclear pores, protein translocation through membrane channels, and viral DNA injection into target cells. Moreover, biological and artificial nanopores embedded in insulating membranes provide useful tools to investigate this process and may find applications in rapid DNA or protein sequencing, single molecule DNA sequencing and analysis, and biomarker sensing. The mechanism of DNA translocation across nanopores has been particularly investigated. The crystal structure of several portal bacteriophage proteins revealed that during DNA packing and injection, dsDNA translocates across a narrow nanopore (~3.5 nm) with a strong negative surface that is decorated by rings of positive charges. The electronegative inner surface of the nanopore is proposed to facilitate the sliding of negatively charged DNA, while the role of the positive charges is thought to facilitate this process. In this Example, it is found that at physiological ionic strengths the electrophoretic translocation of DNA across ClyA nanopores, which have the same fold, size and overall internal charge of portal proteins, can be observed only if two rings of positive charges are engineered at wide-entrance and mid-section of the nanopore. Surprisingly, the strongly electronegative 3.3 nm internal constriction of the nanopore did not require modifications. The findings indicate that the engineered positive charges are important to align the DNA in order to overcome the entropic and electrostatic barriers for DNA translocation through the narrow constriction. Without wishing to be bound by theory, in order to translocate through narrow nanopores with negative charge density a DNA molecule should be oriented.

The ionic current flowing through biological nanopores reconstituted into lipid membranes has been used to identify small molecules or folded proteins and to monitor chemical or enzymatic reactions at the single-molecule level. The electrophoretic translocation of DNA across nanopores reconstituted into artificial membranes holds great promise for practical applications such as DNA sequencing, and biomarker recognition. $\phi 29$ portal protein, which is not a membrane protein *per se*, was found to insert into black lipid bilayers and such nanopores electrophoretically translocated dsDNA at 1.0/0.5 mM NaCl. However, the exact hydrophobic modifications of the nanopore that allowed membrane insertion were not known. Indeed, $\phi 29$ nanopores occasionally released from the lipid membranes, thus posing limitations in practical applications. dsDNA has been shown to translocate through artificial nanopores prepared on solid-state membranes, which with the exception of atom-thin material such as graphene or bilayer of molybdenum disulfide, mostly have a negative internal surface charge. In such nanopores with radii comparable to the Debye length of the solution, the surface potential produced by the electric-double layer (EDL) on the inner nanopore walls overlaps,

resulting in a large electrostatic barrier for the entry of DNA into the nanopore. As a consequence, the translocation of DNA across solid-state nanopores at physiological ionic strength using large nanopores (10 nm) or using small nanopores (~3.5 nm) in 340 nM salt or under asymmetry salt concentrations. Additionally, the translocation of DNA across solid-state nanopores with diameters comparable to the size of DNA (~2.2 nm for the B-form of dsDNA and ~ 1 nm for ssDNA) has yet to be observed at physiological ionic strengths.

The ClyA nanopore, a dodecameric protein with an internal constriction of ~3.3 nm (FIG. 1, Panel A) has been used as a tool to investigate folded proteins. Although dsDNA translocation across the nanopore was observed at 2.5 M NaCl solutions, the strong negative interior of the pore (FIG. 1, Panel A) prevented DNA translocation at lower ionic strengths. In this Example, the ClyA nanopore was engineered, enabling it to translocate of DNA at physiological ionic strengths. This is useful in many applications where electrostatic interactions between molecules and DNA are important, for example in DNA sequencing or mapping where enzymes are used to control the translocation of DNA across the nanopore or to study DNA-protein interactions. The DNA translocation was observed after two rings of positive charges were added at wider *cis* side of the nanopore, while modification of the more constricted *trans* entry of the nanopore did not improve the efficiency of DNA translocation. In addition, the modifications did not change the ion selectivity of the nanopore and mirrored the charge distribution of $\phi 29$ portal protein. Further, the engineered pores allowed the translocation of DNA only from the wide-side of the nanopore. Interestingly, many proteins that slide on DNA display a surface charge similar to the engineered ClyA nanopores, indicating that the alternation of positive and negative charges might provide a general mechanism for improving the translocation of DNA across nanoscales. This Example shows that the precise engineering of the shape and internal surface charge of the nanopore is important for the translocation and sliding of DNA across nano-scale pores with diameter similar to that of DNA.

Results

Engineering ClyA nanopores to capture DNA

ClyA-AS (FIG. 1, Panel A; FIG. 11, Panel A) is an engineered version of cytolysin A from *Salmonella typhi* selected for its favorable properties in planar lipid bilayers and in which the translocation of ssDNA or dsDNA is only observed above 2.0 M NaCl ionic strengths. Most likely, at low ionic strengths, the strong negative electrostatic potential inside the nanopore

(FIG. 11, Panel B) prevents DNA entry and translocation, while at high ionic strengths, the charges of the nanopore surface are effectively screened. To induce the capture of DNA by the nanopores at physiological ionic strengths, the internal charges of the ClyA-AS nanopore were modified (Tables 1 and 2 and FIG. 1, Panel A; FIG. 11, Panel A). Occasionally ClyA variants showed transient reduction of the open pore conductance (gating). As a measurement of gating the gating voltage (VG), defined as the applied voltage at which a typical nanopore remained open for a 30 seconds timespan (Table 1) was used. The translocation of DNA through the modified nanopore was tested at VG by adding 1 μ M of a 90 meric 3' -biotinylated ssDNA molecule (FIG. 1, Panel A, Table 3), followed by its complementary strand at equimolar concentration (FIG. 1, Panel B, Table 3), and finally neutravidin (1.2 μ M, monomer).

A single ring of positive charges in the form of arginine residues was introduced at the *cis* entry of ClyA-AS (S110R, ClyA-R, FIG. 1, Panel A; FIG. 11, Panel A), and then three sections of the nanopore: the *cis* entry, the midsection, and the *trans* constriction were modified (FIG. 1, Panel A; FIG. 11, Panel A). The substitution of neutral residues with positive residues at the *cis* opening of ClyA-R showed no DNA translocation in 150 mM NaCl (Table 1, Table 2). Additional positive charges at the *cis* opening showed either no channel insertion into planar lipid bilayers (ClyA-R-E106R and ClyA-R-D114R) or no DNA translocation in 150 mM NaCl (ClyA-R-D122R and ClyA-R-D129R). Arginine rings in the midsection of the ClyA-R nanopore induced ssDNA (FIG. 1, Panel C) and dsDNA (FIG. 1, Panel D) translocation when the negatively charged glutamate residues at position 64 were replaced by arginine (D64R, ClyA-RR) but not when a neutral side chain at a nearby position was substituted with arginine (Q56R). The substitution of either a neutral side chain at a nearby position with arginine (Q56R), the removal of negatively charged residues in the transmembrane region (ClyA-R-E11S) or the addition of a positively charged residue (ClyA-R-Q8K) induced no DNA translocation events in 150 mM NaCl solutions (FIG. 6). Surprisingly, the substitution of neutral residues with positively charged residues in both the midsection and *trans* entry of ClyA-R (ClyA-R-Q56R-Q8K) also did not induce DNA translocation events (FIG. 6). All mutations tested except ClyA-R-D129R reduced the gating voltage (Table 1). ClyA-RR was the only ClyA mutant that showed DNA induced current events following the addition of either ssDNA or dsDNA to the *cis* side of the nanopore (+70 mV, FIGS. 1C-D and 6). Despite the observation that only ClyA-RR allowed DNA translocation, ClyA-RR, ClyA-R and ClyA-AS all showed the same ion selectivity (P_{Na+}/P_{Cl-} = 1.9 $\pm$ 0.7, 2.0 $\pm$ 1.6, 1.9 $\pm$ 0.9, respectively, Table 4), indicating that the ion selectivity of the nanopore is dominated by the charge distribution of the transmembrane region of the nanopore and is not induced by an enhanced electro-osmotic flow through the nanopore.

More generally, the substitution of the first amino acid in Region A (as denoted in Fig 20) may have at least a delta 1 of added positive charge (namely substitution of a neutral amino acid by a positively charged amino acid) and the substitution in Region B may have at least a delta 2 of added positive charge (namely substitution of a negatively charged amino-acid by a positively charged amino acid).

In order to obtain a greater insight into the changes of the electrostatic potential caused by the two additional arginine rings, full-atom homology models of ClyA-AS and ClyA-RR were constructed using VMD (Humphrey et al. J. Mol. Graphics (1996) 14: 33-38) and NAMD (Phillips et al., J. Comput. Chem. (2005) 26: 1781-1802) starting from the *E. coli* ClyA crystal structure. The adaptive Poisson–Boltzmann solver (APBS), e.g., described in Baker et al., *PNAS* (2001) 98: 10037-10041; Dolinsky et al., *Nucleic Acids Res.* (2004) 32: W665-W667; and Dolinsky et al., *Nucleic Acid Res.* (2007) 35: W522-W525) was employed to calculate the electrical potential distribution of both pores in 150 mM NaCl (FIG. 11, Panel B). In ClyA-AS, the potential at the center of the pore was found to be increasingly negative moving from the *cis* entry, through the midsection, and to the *trans* entry (averaging -2.6 , -4.8 , and -15.2 mV, respectively). In the case of ClyA-RR, a rise in the potential could be observed at both the *cis* entry and the midsection of the pore (averaging -0.3 and -1.1 mV, respectively). The potential in the *trans* constriction appeared to decrease further to an average of -17.3 mV. It should be noted that these values are calculated when no external bias is applied.

Table 1: Electrical properties of engineered ClyA nanopore variants. The activities of the nanopores were tested by adding ~ 0.1 ng of oligomeric proteins to the *cis* chamber. A negative activity indicates that no channel insertions were observed. VG is the gating voltage and represents the highest applied voltage at which no gating events were observed within a 30-second timespan. DNA translocation indicates that a dsDNA rotaxane could be formed. Each data point is the average of at least three experiments and the error is the standard deviation. Experiments were carried out in 0.15 M NaCl, 15 mM Tris HCl, pH 7.5 solutions.

Table 1

Pore variants	Bilayer activity	$I_{O+100mV}$ $I_{O1-00Mv}$ (pA)	Rectification ratio	VG (mV)	DNA Capture (<i>cis</i>)	DNA Translocation (<i>cis</i>)
ClyA-AS	+	$+190 \pm 13$ -138 ± 6	1.4 ± 0.1	+100	-	-
ClyA-AS-S110R (ClyA-R)	+	$+198 \pm 1$ -127 ± 2	1.6 ± 0.0	+100	-	-
ClyA-R-E106R	-	-	-	-	-	-

ClyA-R-D114R	-	-	-	-	-	-
ClyA-R-D122R	+	+207±2 -99.8±2	2.1±0.1	+50	-	-
ClyA-R-E129R	+	+171±25 -161±24	1.1±0.2	+100	-	-
ClyA-R-D64R (ClyA-RR)	+	+198±8 -110±4	1.8±0.1	+70	+	<i>cis</i>
ClyA-R-Q56R	+	+202±8 -128±3	1.6±0.1	+50	-	-
ClyA-R-Q8K	+	+202±15 -147±18	1.4±0.2	+50	-	-
ClyA-R-E11S	+	+194±4 -154±0	1.3±0.03	+70	-	-
ClyA-R-Q56R-Q8K	+	+207±20- 150±15	1.4±0.2	+50	-	-

DNA rotaxane as a proof of DNA translocation

A rotaxane is a dumbbell shaped molecule formed by a macrocycle that encircles a thread locked by two stoppers. In this Example, two nanopore/DNA rotaxanes were formed in 150 mM NaCl solutions to prove the translocation of ssDNA and dsDNA through the nanopore. The first rotaxane was formed using a 100 mer 5'-biotinylated ssDNA molecule as the initial thread (**2a**, Table 3) added to the *cis* compartment. The second rotaxane was formed using a 3'-biotinylated 59 base pairs dsDNA molecule extended with a 31 bases 3' biotin overhang (**1a/1c**, Table 3). The rotaxanes were locked by adding on the opposite side of the nanopore another biotinylated ssDNA molecule, **2b** (50 mer, 5'-biotinylated) or **1d** (31 mer, 3'-biotinylated), designed to hybridize with the overhangs of **2a** or **1a/1c**, respectively. Both *cis* and *trans* solutions contained Neutravidin (NA, 0.3 μM), which complexed with biotin and prevented the full translocation of the DNA strands across the nanopore.

In 150 mM NaCl and at +50 mV, both ssDNA and dsDNA/ssDNA threaded the nanopore (IRES+50 92±0.02, and 0.84±0.07, respectively, N=3), but were ejected from the pore when the applied potential was reversed to -50 mV (FIG. 2, Panels A-B). The subsequent addition of the DNA:neutravidin stoppers to the *trans* solutions induced a permanent blockade at both potentials, indicating the assembly of a DNA rotaxane, and showing that both threads translocated the nanopore. At negative applied potentials the blocked ionic current was higher than the open pore current for both rotaxanes (IRES-50 = 1.16±0.03 and 1.11±0.06, for ssDNA and dsDNA/ssDNA threads, respectively, N=3 independent nanopore experiments, FIG. 2, Panels, A-B; FIG. 12, Panels A-B). This effect was previously observed for the translocation of

DNA through 10 nm solid-state nanopores at low ionic strengths and was explained by the accumulation of counterions inside the DNA blocked pore. By contrast, at positive applied potential the open pore current was higher than the blocked current (FIG. 1, Panels C-D and FIG. 2, Panels A-B; FIG. 12, Panels A-B), indicating that in this configuration neutravidin might interact with the lumen of the nanopore and that the accumulation of counterions on the DNA differs at the *cis* and *trans* sides of the nanopore.

DNA Capture/ threading and translocation depends on the ionic strength of the solution

The capture rate k_{on} , which is the inverse of the inter-event time inverse of the inter-event time τ_{on} (Table 7, +70 mV, 1 μM DNA), increased with the Debye length of the solution (λ_D) for both ssDNA and dsDNA (FIG. 3, Panels B-C; FIG. 13, Panels A-B). However, while the dsDNA capture rate increased linearly with λ_D (FIG. 13, Panel A), ssDNA capture rate increased exponentially with λ_D (FIG. 13, Panel B). This indicates, therefore, different capture mechanisms for dsDNA and ssDNA. The frequency of dsDNA translocation, added on the *cis* side, increased linearly with the Debye length of the solution (+70 mV, FIGS. 3A, 7 and 8), indicating that the electrostatic interactions between the DNA and the nanopore are important for DNA entry and translocation. As reported before with solid-state nanopores, the residual current of DNA blocked nanopores increased as the ionic strength of the solution decreased (e.g., from 0.78 ± 0.09 in 2.5 M NaCl to 0.92 ± 0.02 in 150 mM NaCl). Interestingly, it was found a linear relationship between the IRES of the DNA blockades and the Debye length of the solution (FIG. 3, Panels B-C). For dsDNA in complex with Neutravidin the residual current was ~10% lower than during free DNA translocation, indicating that Neutravidin contributed to the overall ionic current of the blockade, most likely by interacting with the nanopore lumen.

The frequency of ssDNA translocation increased exponentially ($R^2=0.99$) rather than linearly ($R^2=0.78$) with the Debye length of the solution (FIG. 3, Panel C), indicating that additional factors other than the interaction between the engineered positive charges in the ClyA lumen and DNA play an important role for the nanopore entry and /or translocation. At 150 mM NaCl, ssDNA molecules in complex with Neutravidin showed permanent blockades to ClyA-RR nanopores, while at 1 M NaCl or higher, the blockades were transient (FIG. 3, Panel D, FIG. 10). A likely explanation for these data is that at high ionic strengths ssDNA entered and escaped the pore from the *cis* side. At ionic strengths ≥ 1 M the IRES values for ssDNA in the presence and absence of Neutravidin were the same (FIG. 3, Panel C; FIG. 10), indicating that under these conditions ssDNA might not fully thread the nanopore, preventing Neutravidin from interacting with the lumen of ClyA.

Unidirectional entry of DNA into ClyA nanopores

In 150 mM NaCl solutions and under negative applied potentials (up to -100 mV), the addition of 1 μ M of ssDNA or dsDNA to the *cis* and *trans* compartments of ClyA-RR did not induced DNA blockades, indicating that DNA cannot enter the nanopore from the *trans* entrance of the nanopore (FIG. 4, Panel A). Under a positive applied bias, the current blockades appeared at potentials higher than $\sim +50$ mV, suggesting the existence of a voltage threshold for the translocation of ssDNA from the *cis* side of the nanopore. The entry (FIG. 4, Panel B) and translocation (FIG. 9) of DNA from the *trans* compartment, however, was observed in 1 M NaCl solutions, indicating that the energy barrier that prevents the translocation from the *trans* compartment at 150 mM NaCl is electrostatic in nature.

To observe the entry of DNA from the *trans* compartment under physiological ionic strengths, the charges of the transmembrane region of ClyA-RR nanopores were remodeled (Table 5 and FIG. 10). It was found that the substitution of the negatively charged residue in the transmembrane region of the nanopore did not induce current blockades upon the addition of 1 μ M of dsDNA 1 to the *trans* chamber under negatively applied potentials (FIG. 10), indicating a relatively large asymmetric barrier for the translocation of DNA from the *cis* and *trans* sides of the ClyA-RR nanopore under these conditions.

Discussion

Precise nanopore engineering supports DNA translocation at physiological ionic strength

In this Example, ClyA nanopores were engineered to allow the electrophoretic translocation of DNA at physiological ionic strengths. DNA translocation was observed when two sets of positive charges were introduced at the entry and in the midsection of the ClyA nanopore (FIG. 11, Panel A). Surprisingly, the *trans* entry of the nanopore, which provides the highest entropic and electrostatic barriers for DNA translocation (FIG. 11, Panels A-B), did not require modification. Further, despite extensive remodeling to the charge of the *trans* entry of ClyA (Tables 1-2), DNA translocation could be observed only when initiated from the wider *cis* entry of the nanopore. Moreover, the frequency of dsDNA translocation through ClyA-RR nanopores increased with the Debye length of the solution (FIG. 13, Panel A), showing that the favorable electrostatic interactions of dsDNA with the *cis* entry of ClyA-RR dominate over the unfavorable electrostatic repulsion of the DNA with the nanopore constriction. It should be noted that the stiffness of dsDNA does not change significantly over the range of ionic strength tested. Further, the increased electro-osmotic flow as the ionic strength is lowered cannot account for the increased frequency of DNA translocation because the electro-osmotic flow opposes DNA entry and translocation. These data indicate, therefore, that the *cis* lumen of the nanopore is important to initiate the translocation of DNA through the constriction of the

nanopore.

A DNA molecule translocating through a nanopore is subjected to the electrical driving force, and the hydrodynamic viscous drag force arising from the electroosmotic flow (EOF) inside the nanopore that opposes the translocation of DNA. ClyA and most solid-state

5 nanopores have a negative surface charge that is electrostatically balanced by a layer of cations in the immediate contact with the surface usually called electric double layers (EDL). Under the applied electric field, the movement of the ions in the EDLs induces the preferential translocation of the counterion, which in turn generate an EOF and makes the nanopore ion selective (*e.g.*, ClyA-AS $P_{Na}/P_K=1.9$, Table 2). Due to the screening by the electrolyte, the EDL
10 force decays in an exponential fashion over the diffuse layer. The range of this force is given by the Debye length and its strength by the surface potential. In narrow nanopores, especially in the regime of low salt concentration, the thickness of the EDLs including the diffuse layer might be comparable to the size of the nanopores, yielding overlapped EDLs. Under this regime a DNA molecule (diameter 2.2 nm) approaching such nanopores will experience a strong surface
15 potential that for nanopores with negative surface charge will oppose the entry of DNA into the nanopore.

Mechanism of dsDNA and ssDNA translocation through ClyA nanopores

ClyA can be approximated by a cylindrical *cis* lumen (5.5 nm diameter and 10 nm
20 length) followed by a smaller and negatively charged *trans* constriction (3.3 nm diameter and 3.0 nm length, FIG. 1), which is expected to oppose the main electrophoretic and entropic barrier for DNA translocation. Surprisingly, the translocation of DNA through ClyA nanopores was observed when a set of positive charges was added to the *cis* lumen of the nanopore (ClyA-RR); while the constriction of the nanopore did not require any modification. Despite extensive
25 modification to the *trans* entrance of ClyA (Table 2), DNA translocation could be observed only when initiated from the wider *cis* side of the nanopore, suggesting that the *cis* lumen of the nanopore is important to initiate the translocation of DNA through the nanopore. The frequency of double stranded DNA translocation through ClyA-RR nanopores increased linearly with the Debye length of the solution (FIG. 3, Panel A), indicating that the electrostatic interactions of
30 dsDNA with the engineered charges in ClyA-RR favor rather than oppose the translocation process. A model is proposed for where the translocation of dsDNA through the *trans* constriction at physiological ionic strengths is obtained when the dsDNA strand is pre-aligned by the *cis* lumen of the nanopore (FIG. 5, Panel A). In this view, the dsDNA initially interacts with the charges at the *cis* entry and then enter the lumen of the pore where it further interacts
35 with the arginine residues at the mid-section of the nanopore (FIG. 1, Panel A). These

electrostatic interactions “grab” the phosphate groups of DNA preventing the exit of the DNA back to the *cis* solution. In this configuration, the dsDNA is aligned to enter the *trans* constriction, where the electrophoretic force is the strongest, allowing the smooth translocation of DNA across the nanopore (FIG. 5, Panel A).

It was observed that the Debye length dependency of ssDNA blockades fitted well to a single exponential (FIG. 3, Panel A) rather than a linear function as observed for dsDNA, suggesting that additional factors influence the translocation of ssDNA compare to dsDNA. In the experiments, the DNA contour length, which is the total length of the DNA when it is stretched completely, is lower than the persistence length of dsDNA (~50 nm), indicating that the dsDNA molecules translocate as a rigid rod (FIG. 5, Panel A). By contrast, ssDNA has a coiled structure (persistence length ~1.5 nm) with a gyration radius, which is the average squared distance of any point in the polymer coil from its center of mass, of ~6 nm. Since the gyration radius is similar to the diameter of the *cis* entrance of the nanopore (FIG. 5, Panel B), ssDNA most likely enters the *cis* side of the nanopore as a partially coiled structure (FIG. 5, Panel B). As the ssDNA moves from the *cis* reservoir to the *trans* side, it must then gradually uncoil in order to navigate through the *trans* constriction of the nanopore and then recoil on the opposite side (FIG. 5, Panel B). This entropic uncoiling and recoiling force related to the conformational change of DNA in transition, which at high ionic strengths promotes the *cis* ejection of immobilized ssDNA from the nanopore against the applied potential (FIG. 3, Panel D), decreases with decreasing the ionic strength of the solution, augmenting the efficiency of DNA translocation as the ionic strength of the solution is reduced. It should be noted that the ion concentration and Debye length inside the DNA blocked nanopores are not known. Nonetheless, both correlate to the nanopore current, which in turn is linked to the concentration of bulk electrolyte (FIG. 3, Panels B and C).

Mechanism of DNA Translocation: dsDNA Capture is Diffusion-Limited and ssDNA Capture is Reaction-Limited

The DNA translocation experiments at different salt concentrations showed two different capture mechanisms for dsDNA and ssDNA (FIG. 13, Panels A-B, and FIG. 14, Panels A-B, respectively). The behavior of dsDNA is consistent with a diffusion-limited capture process. This is because the dsDNA used in this work is shorter than its persistence length (150 bp) and behaves as a rigid uniformly charged rod. Within the capture radius (about 50 nm from the nanopore center for a λ_D of 0.5 nm), the electric field attracts the DNA toward the pore and aligns it along the field lines so that it hits the pore entry with one end (FIG. 14, Panel A, i). Once inside the pore, the engineered charges interact with the DNA, preventing the retraction

back to the *cis* solution (FIG. 14, Panel A,ii–iv). Therefore, the dynamics of DNA capture can be approximated by that of a diffusing particle in a purely attractive potential of electrophoretic origin. In this case, the electrophoretic mobility of the dsDNA is proportional to the Debye length of the solution and the corresponding drift–diffusion equation can be solved exactly, which is further described in detail below. By approximating the geometry of the ClyA nanopore with a cylinder of length $l = 13$ nm and a capture diameter $d = 6$ nm (FIG. 11, Panel A), the capture frequency can be estimated by the following:

$$k_{\text{on}} \sim 14\lambda_D (\text{s nm } \mu\text{M})^{-1}$$

This is in remarkably good agreement with the experimental data for λ_D (at high salt concentrations, FIG. 13, Panel A). This is striking because no fitting parameters are used.

However, some care should be taken in this comparison, as the choice of the pore parameters is to some extent arbitrary since ClyA's geometry deviates significantly from a perfect cylinder. At low salt concentrations (0.15 M NaCl, $\lambda_D = 0.8$ nm), the capture rate is higher than predicted by the equation above (FIG. 13, Panel A). Likely, the positive charges at the ClyA-RR entry, which are not taken into account in the model, speed up the capture at low salt concentrations, while at higher salt concentrations, these charges are more effectively screened.

For ssDNA, the relation between k_{on} and λ_D is exponential, which is consistent with a barrier crossing (reaction-limited process). In solution, the ssDNA assumes a coiled conformation while it is pulled toward the nanopore by the electrophoretic force as DNA approaches the nanopore (FIG. 14, Panel B,i). In the vicinity of the entry of the pore, however, a successful translocation event can only take place if one end of the strand faces the pore entry (FIG. 14, Panel B,ii) and if the ssDNA is uncoiled (FIG. 14, Panel B,iii,iv). This additional repulsive force of entropic origin effectively results in an energy barrier that must be crossed prior to translocation. The theory of such barrier-limited translocation has been discussed and on

general grounds, the capture rate is given by: $k_{\text{on}} = \omega e^{-\Delta F_b/k_B T}$

Here, ΔF_b is the barrier height and ω is a characteristic attempt rate for barrier crossing. The exponential factor gives the probability of a successful crossing event. Estimating ΔF_b from model inputs can be accomplished; it was shown that the probability of successful translocation contains a term proportional to the electrophoretic mobility, which in turn is proportional to λ_D . This would explain the exponential dependence of k_{on} on λ_D (FIG. 13, Panel B). It should be noticed that while k_{on} is obtained from the inverse inter-event time, not all measured current blockades necessarily describe a translocation event. Part of these blockades may be due to the entry of a DNA strand followed by a retraction back to the *cis* side (FIG. 14, Panel B, iii to i). Nevertheless, the formation of rotaxanes shows that at least some molecules

successfully translocate. In any case, the argument leading to an exponential dependence of k_{on} on λ_D remains valid.

Biological significance

Interestingly, the modifications that allowed the translocation of DNA through ClyA
 5 nanopores are also observed in proteins which biological function is to slide along DNA. In
 bacteriophages, DNA is transferred into the procapsid by packing proteins that align and push the
 DNA through portal proteins that have similar dimension, stoichiometry, internal surface charge,
 and internal constructions size similar to that of ClyA. A negative internal surface charge
 appears to be important for the smooth translocation of DNA across the portal proteins, as it
 10 is observed in other proteins that encircle and slide along DNA such as β -clamp proteins. Portal
 proteins and β -clamp proteins also have positively charged rings that have been proposed to play
 a direct role in genomic DNA packaging by interacting with the negatively charged phosphate
 backbone of the translocating DNA. The electrophoretic translocation of DNA through ClyA
 nanopores could be observed when two rings of positive charged residues are introduced at the
 15 *cis* entrance and mid- section of the nanopore, aligning the DNA for the passage through the
 narrow and electronegative constriction. In the absence of such interactions, that is, during the
 threading from the *trans* side, DNA translocation could not be observed. The results presented
 herein indicate, therefore, that in connector proteins such rings of positive charges might be
 important to initiate the ejection of the DNA out of the capsid into the infected cell.

Presented in this Example is an engineered ClyA dodecameric nanopore, ClyA-RR,
 20 upon introduction of two rings of positive charges, to translocate dsDNA and ssDNA at
 physiological ionic strengths. ClyA-RR can be used to study protein-DNA interactions at the
 single-molecule level and can be employed in DNA mapping and sequencing applications,
 where an enzyme controls the translocation of the nucleic acid through the nanopore. It was
 25 found that the introduction of rings of positive charges, attractive interactions, at the wider entry
 (the *cis* side) of the nanopore is important to induce DNA translocation through the narrow and
 negatively charged *trans* constriction. Surprisingly, the constriction itself did not require
 modifications. These results indicate that attractive interactions at the entry and in the middle of
 the nanopore are important to “grab” and orient the DNA for effective electrophoretic-driven
 30 sliding through the narrow and negatively charged *trans* constriction. Interestingly, the charge
 distribution in ClyA-RR is mirrored in viral portal proteins, indicating that the precise
 engineering of biological nanopores is important for the efficient packing and ejection of DNA
 in and out the viral capsid. Further, the linear and exponential ionic strength dependencies of the
 frequency of dsDNA and ssDNA translocations, respectively, indicate a likely mechanism

where the dsDNA capture follows a diffusion-limited process, while the ssDNA capture a reaction-limited process. It was also showed that ssDNA enters the nanopore as a coiled structure that needs to be uncoiled in order to translocate through the constriction of the nanopore. These finding can be used to help the engineering of solid-state nanopores. For example, a nano-scale chamber with a favorable surface charge and a diameter similar to the gyration radius of DNA placed above the nanopore should favor the translocation of DNA, especially at low ionic strengths. In addition, it was found that the modifications to the ClyA nanopore that allow DNA translocation are mirrored in viral portal proteins, indicating that the precise engineering of biological nanopores is important for the efficient packing and ejection of DNA in and out the viral capsid.

Exemplary Materials and Methods

DNA was purchased from Integrated DNA Technologies (IDT). Neutravidin was acquired from Thermo Fisher and 1,2-diphytanoyl-*sn*-glycero-3-phosphocholine from Avanti Polar Lipids. β -Dodecyl maltoside (DDM) was purchased from GLYCON Biochemicals GmbH. Enzymes were bought from Fermentas and all other materials from Sigma, unless otherwise specified.

Protein purification. Single-point mutations to the ClyA-AS gene were performed by using the “mega primer” method as described in Soskine et al., *J. Am. Chem. Soc.* (2013) 135: 13456-13463 and Miyazaki et al., *Methods Enzymol.* (2011) 498: 399-406. ClyA was expressed in *E. coli* BL21 (DE3) cells by using a pT7 plasmid. Monomers were purified by using Ni-NTA affinity chromatography and oligomerized in the presence of 0.5% β -dodecyl maltoside (GLYCON Biochemicals GmbH) as described in Waduge et al., *ACS Nano* (2015) 9: 7352-7359. Monomers (containing a C-terminal oligo-histidine tag) were expressed in *E. coli* BL21 cells and the soluble fraction purified using Ni-NTA affinity buffer (150 mM NaCl, 15 mM Tris HCl, pH 7.5, 0.2% DDM and 1 mM EDTA) and stored at 4°C.

DNA preparation. dsDNA 1 was prepared by first mixing equimolar concentrations of **1a** and **1b** (Table 3). The mix was brought to 95°C and the temperature stepped down at regular intervals. The DNA was purified from the excess of ssDNA with affinity chromatography using a biotin-binding column containing monomeric avidin immobilized on agarose beads (Thermo Scientific Pierce). The ds DNA was then eluted from the column according to the manufacturer’s protocol. The elution fraction was concentrated and further purified using a PCR quick purification kit (QIAGEN). Typically, a DNA concentration of 0.2µg/mL was obtained. **1a/1c** duplex was annealed as explained for 1 but not purified.

Ion permeability. *I–V* curves under asymmetric conditions (Table 6) were collected by adding ClyA to the *cis* chamber under symmetric conditions (150 mM NaCl, 15 mM Tris-HCl pH 7.5 in both *cis* and *trans* solutions). The electrodes were then balanced, and the electrolyte

concentration in *cis* was increased up to 1 M by adding aliquots of 5 M NaCl stock solutions to the *cis* compartment. The volume of the *trans* chamber was adjusted by adding the same volume added to the *cis* side using the same buffer of the *cis* solution (150 mM NaCl).

Permeability ratios ($P_{\text{Na}^+}/P_{\text{Cl}^-}$, Table 4) were calculated using the Goldman–Hodgkin–Katz equation (below) using the measured reverse potential (V_r) values, which were extrapolated from the *I–V* curves.

$$P_{\text{Na}^+}/P_{\text{Cl}^-} = \frac{[a_{\text{Cl}^-}]_{\text{trans}} - [a_{\text{Cl}^-}]_{\text{cis}} e^{V_r F/RT}}{[a_{\text{Na}^+}]_{\text{trans}} e^{V_r F/RT} - [a_{\text{Na}^+}]_{\text{cis}}}$$

R is the universal gas constant (8.314 J K⁻¹ mol⁻¹), T the temperature in Kelvin, F the Faraday's constant (96 485 C mol⁻¹), P_{Na^+} and P_{Cl^-} are the relative membrane permeability for the ions Na⁺ or Cl⁻, and a_{Na^+} and a_{Cl^-} are their respective activities. The *cis* chamber was the ground.

Ag/AgCl electrodes with 2.5% agarose bridges containing 2.5 M NaCl were used to perform all of the experiments.

Electrical Recordings. Ionic currents were measured by recording from planar bilayers formed from diphytanoyl-*sn*-glycero-3-phosphocholine (Avanti Polar Lipids, Alabaster, AL). Currents were measured with Ag/AgCl electrodes submerged in agar bridges (3% w/v low-melt agarose in 2.5 M NaCl buffer) using a patch-clamp amplifier (Axopatch 200B, Axon Instruments, Foster City, CA) as described in Ho et al., *Sci. Adv.* (2015) 1, e1500905; and Maglia et al., *Methods Enzymol.* (2010) 475: 591–623. Single channels were characterized by measuring the current versus applied voltage relationship (*I–V* curve, the potential was applied in 10 mV steps from –100 to +100 mV in 21 s, FIGs. 6, 10 and Table 5). In 0.15 M NaCl, ionic currents were recorded by applying a 2 kHz low-pass Bessel filter and using a 10 kHz sampling rate. At higher salt concentrations, ionic currents were sampled at 50 kHz and the low-pass Bessel filter was set at 10 kHz. Current traces at 0.3 and 0.5 M NaCl were filtered post-acquisition with a 4 kHz Bessel digital filter (FIGs. 16, 17). The use of different filtering frequencies influences the overall number of detected events. For example, applying a 2 kHz digital Gaussian filter to a trace sampled at 50 kHz while applying a 10 kHz Bessel filter increases the inter-event time by about 50% (from 221 to 311 ms, 0.17 μM dsDNA, 1 M NaCl, average dwell time of 0.12 ms).

Therefore, to test the effect of excessive filtering on the Debye length dependence of the DNA capture frequency, the data described in FIG. 13, Panel A were plotted after applying a 1 kHz Gaussian filter to all current traces (FIG. 18). It was found that the ssDNA and dsDNA blockades fitted well to an exponential and a linear regression, respectively (FIG. 18).

5

Data analysis. Current blockade events were collected individually by using the “single channel search” function of the Clampfit software (Molecular Devices) using a data acquisition threshold of 0.05 ms. Open and blocked pore current were obtained were calculated from Gaussian fitting to all-point histograms. Residual currents were calculated by dividing the blocked pore current values for the open pore current values. The DNA translocation dwell times (τ_{off}) values were calculated from a single exponential fit from event histograms of DNA blockade dwell-times, while (τ_{on}) values were calculated using an exponential logarithmic probability fit from logarithmic histograms of the inter-event times (FIG. 13, Table 7, and FIGs. 16, 17). The errors indicate the standard deviation from the average from at least three independent nanopore experiments, the number of which is indicated by N.

10

15

Additional information about preparation of the modified ClyA nanopore subunit polypeptide according to one embodiment described herein

Single point mutations to the ClyA-AS gene were performed by using the “mega primer” method. Typically, two PCR cycles were performed to prepare a new DNA construct: In the first PCR reaction the plasmid DNA was amplified with two primers: the forward primer was a oligonucleotide 20-30 bases in length that carried the base substitution, the reverse primer was either the T7 promoter or T7 terminator. For mutations at the transmembrane region the reverse primer was a 25 mer oligo complementary to a stretch in the middle of protein sequence (Table 3). The PCR product containing the mega primers (200-300 bp), was loaded into an agarose gel (2% agarose/ TAE and crystal violet), the megaprimer cut out and purified using a PCR quick purification kit (QIAGEN). 5 μ L of purified mega primers were loaded on 2% agarose/TAE gel to check for purity and 5-10 μ L of the megaprimer were employed for a 2nd PCR reaction. The 2nd PCR product was then first digested with DpnI (1-2 h, 37°C, fast digest DpnI, Fermenthas) to eliminate the ClyA-AS template DNA and then ~1 μ L used for transformation with electrocompetent cells *E. coli*® EXPRESS BL21 (DE3) (maker).

25

30

Additional information about DNA preparation

dsDNA 1 was formed by incubating 1a, 3'-biotinylated ssDNA molecule (Table 3), with a 20% excess of complementary ssDNA 1b (Table 3). The temperature was brought to 95°C for

35

1 min and then decreased stepwise to room temperature. At around the estimated annealing temperature of 70°C, the temperature was decreased in 2°C steps to 21°C. Each step lasted for 1 minute. The DNA was then purified from the excess of ssDNA with affinity chromatography using a biotin-binding column containing monomeric avidin immobilized on agarose beads (Thermo Scientific Pierce). The dsDNA was then eluted with Biotin Blocking/Elution Buffer according to the manufacturer protocol. The elution fraction was concentrated and further purified using a PCR quick purification kit (QIAGEN). Typically, a DNA concentration of 0.2 µg/mL was obtained. The size and purity of the dsDNA was checked by using a 2% agarose gel in TAE buffer and quantified spectroscopically. The purified dsDNA was stored at -20°C in the presence of 1 mM EDTA. 1a:1c was formed by incubating a 3'-biotinylated ssDNA molecule (1a, Table 3) with equal molar concentration of a 1c. The temperature was brought to 95°C for 1 minute and then decreased stepwise to room temperature. At around the estimated annealing temperature 70°C, the temperature was decreased in 2°C steps, each held for 1 minute.

15 ***Additional information about electrical recordings and data analysis***

Artificial planar lipid bilayers were prepared as described above. If not otherwise specified, the signal was collected at a sampling rate of 50 kHz after processing with a 10-kHz Bessel filter. The lipid bilayer was formed by pretreating a small aperture (~ 100 µm) on a Teflon film (Goodfellow, UK) with 1–2 µl of a 10% solution of 1,2-diphytanoylsn- glycerophosphocholine in pentane. The electrical potential was applied by using Ag/AgCl electrodes submerged in agar bridges (3% w/v low melt agarose in 2.5 M NaCl buffer). The applied potential refers to the potential of the working electrode connected to the *trans* compartment of the apparatus. ClyA nanopore solutions (0.01–0.1 ng/mL) were added to the *cis* compartment, which was connected to the ground electrode. After the insertion of a single pore, excess protein was removed by several cycles of perfusion. Electrical recordings were carried out in 0.15–2.5 M NaCl, 15 mM Tris HCl, pH 8.0, at 22°C. In 0.15 M NaCl data were recorded by applying a 2-kHz low-pass Bessel filter and using a 10 kHz sampling rate. While at higher salt concentration data were sampled at 50 kHz and the low-pass Bessel filter was set at 10 kHz. Current traces at 0.3 and 0.5 M NaCl were filtered post-acquisition with a 4-kHz Bessel digital filter. Current blockade events were collected individually by using the “single channel search” function of the Clampfit software (Molecular devices) using a data acquisition threshold of 0.05 ms. I_O and I_B values were calculated from Gaussian fitting to all-point histograms of the open and blocked pore currents, respectively. The DNA translocation dwell time τ_{off} was calculated by a single exponential standard fits from an event histogram of the block pore current events (t_{off}). The inter-event time τ_{on} was calculated by using an exponential logarithmic probability fit

from the logarithmic histogram of the inter-event times (t_{on}) between block pore current events. The errors indicate the standard deviation from the average from at least three independent repeats, the number of which is indicated by “n.”

Pores inserted from the *cis* chamber showed higher conductance at positive applied potential, helping to assess the orientation of the inserted channel. Single channels were characterized by measuring the current versus applied voltage relationship, (I-V curve, the potential was applied in 10 mV steps from -100 to +100 mV in 21 seconds). The pore rectification was obtained from the ratio of the open pore current at +100 mV and that at -100 mV ($I_{0+100mV}/I_{0-100mV}$). The propensity for gating of the nanopores was assessed by the continuous measurement of the open pores current at a given applied potential. V_{MAX} was then given by the applied potential at which no gating events were observed within a 30 second timespan. Spontaneous reversible gating of the ionic current were observed at applied voltages higher than V_{MAX} . DNA entry and translocation through the pore was tested by adding 1 μ M of 3' end biotinylated ssDNA 1a followed by the addition of the complementary ssDNA 1b (Table 3) and then neutravidin (1.2 μ M, monomer) to the *cis* chamber under an applied potential equal to V_{MAX} .

Additional information about ionic permeability

Permeability ratios for ClyA nanopores were calculated by measurement of the reversal potential in asymmetric salt condition: 150 mM NaCl *trans*, 1 M NaCl *cis*. The protein nanopores were added to the *cis* chamber and a single channel was first characterized in symmetric condition (150 mM NaCl, 15 mM Tris HCl pH 7.5 in both *cis* and *trans* solutions). After the electrodes were balanced, the electrolyte concentration in *cis* was increased up to 1 M, by adding aliquots of 5 M NaCl stock solutions to the *cis* compartment. The volume of the *trans* chamber was adjusted by adding the same volume added to the *cis* side using the same buffer of the *cis* solution (150 mM NaCl). The reversal potential (V_r , Table 3), which is the electrical potential used to obtain a zero current, was obtained by current-voltage (IV) curve (Table 6). Ion selectivities (P_{Na^+}/P_{Cl^-}) were calculated from the V_r by using the Goldman-Hodgkin-Kats (GHK) equation. According both to the GHK equation positive value for V_r observed for the ClyA nanopores show a preferential movement of the cations through the pore, indicating that the pores are cationic selective channels. The *cis* chamber was at ground and Ag/AgCl electrodes with 2.5% agarose bridges containing 2.5 M NaCl were used to perform all the experiments.

$$P_{Na^+}/P_{Cl^-} = \frac{[a_{Cl^-}]_{trans} - [a_{Cl^-}]_{cis} e^{VF/RT}}{[a_{Na^+}]_{trans} e^{VF/RT} - [a_{Na^+}]_{cis}}$$

where V_r is the membrane potential, R the universal gas constant ($8.314 \text{ J.K}^{-1}\text{.mol}^{-1}$), T the temperature in Kelvin F the Faraday's constant (96485 C.mol^{-1}), P_x the relative membrane permeability for Na^+ and Cl^- , $[a_x]_{cis}$ the activity of Na^+ and Cl^- in the *cis* compartment, $[a_x]_{trans}$ the concentration of Na^+ and Cl^- in the *trans* compartment, and a_x the activity of Na^+ and Cl^- (J.F. Zemaitis, Handbook of aqueous electrolyte thermodynamics: theory and application, 1986; Ludwig Molecular Microbiology 1999; Li-Qun Gu PNAS 2000; Petr G. Merzlyak Biophysics 2005).

Details are presented on the derivation of Eqs. (1) and (2), describing the capture rates of dsDNA and ssDNA, respectively.

dsDNA capture

The approach relates to one developed by Grosberg and Rabin. The ClyA nanopore-membrane is described as a planar dielectric surface of thickness l with a cylindrical hole of diameter d . Characteristic distances for a ClyA pore are $l = 13 \text{ nm}$ and $d = 6 \text{ nm}$. Using ΔV to represent the potential difference between the *cis* and *trans* side of the membrane, it can be shown that the electric potential in the *cis* side is given by:

$$V(r) = \frac{d^2}{8lr} \Delta V \quad (1)$$

which decays as $1/r$ far from the pore at the *cis* side (by convention the potential at the electrode in the *cis* side was set to zero). The origin of the coordinates ($r = 0 \text{ nm}$) is the middle of the pore (Fig. 19).

The dsDNA is approximated as a charged point particle performing a diffusive motion with diffusion constant D and with an electrophoretic drift characterized by an electrophoretic mobility μ . The resulting drift-diffusion equation in radial coordinates for the dsDNA concentration $c(r,t)$ is given by:

$$\frac{\partial c}{\partial t} = \frac{1}{r^2} \frac{\partial}{\partial r} \left[D r^2 \frac{\partial c}{\partial r} - \mu r^2 c \frac{\partial V}{\partial r} \right] \quad (2)$$

where the minus sign in front of the electrophoretic current is because the DNA is negatively charged. In this convention the mobility coefficient positive $\mu > 0$ is kept, hence the drift velocity due to an applied electric field is $v = -\mu E$. Note that the Einstein relation does not hold for this system (i.e., $D \neq \mu k_B T$), hence one cannot simply relate D and μ .

The stationary solution ($\partial c / \partial t = 0$) of Eq. (2) is:

$$c(r) = c_0 \frac{1 - e^{-r^*(1/R - 1/r)}}{1 - e^{-r^*/R}} \quad (3)$$

where the boundary conditions are: $c(R) \rightarrow c_0$ at infinity and $c(R)=0$ with R a microscopic distance of the order of the pore size. The distance r^* is defined as:

$$r^* = \frac{\mu d^2 \Delta V}{8 D l} \quad (4)$$

5 which allows us to rewrite the electrophoretic potential (1) as:

$$V(r) = \frac{D}{\mu} \frac{r^*}{r} \quad (5)$$

From the solution (3) and the previous relation one obtains the radial particle current density:

$$j(r) = -D \frac{\partial c}{\partial r} + \mu c \frac{\partial V}{\partial r} = \frac{D r^* c_0}{r^2} \frac{1}{1 - e^{-r^*/R}} \quad (6)$$

10 And the rate is obtained from integrating the current density over a half spherical shell of radius r (accounting for the surface available on the *cis* side):

$$k_{on} = 2\pi r^2 j(r) = \frac{2\pi D r^* c_0}{1 - e^{-r^*/R}} \approx 2\pi D r^* c_0 \quad (7)$$

where the approximation $r^* \gg R$, validity was checked later. The final result formally resembles the Smoluchowski diffusion-limited reaction rate for a diffusive particle in absence of an external potential. Here r^* can be interpreted as the distance at which the dsDNA is irreversibly captured by the pore. This capture radius increases at higher applied potential or for increased electrophoretic mobility (4).

15

Combining (4) and (7) one obtains:

$$k_{on} = \frac{\pi d^2 \Delta V c_0 \mu}{4 l} \quad (8)$$

Note that D cancels out from the previous equation since r^* is inversely proportional to D .

20 To proceed further μ was estimated. The total charge on a dsDNA molecule with length L is $Q = -2\alpha e L a$ where $a = 0.34$ nm is the distance between two bases and $\alpha < 1$ is a numerical

coefficient which reflects the fact that not all of the phosphate groups are ionized.

Approximating the DNA as a cylinder of surface area A , the drag force was estimated as $(\eta A \lambda_D) v$ where $\eta = 10^{-3} \text{ kg m}^{-1} \text{ s}^{-2}$ is the water viscosity and λ_D the Debye length. Using the definition $v = -\mu E$ one gets:

$$\mu = \frac{2\alpha\lambda_D}{\eta\pi ab} \quad (9)$$

where $b = 2 \text{ nm}$ is the double helix diameter. An alternative derivation of this equation, based on the calculation of the ζ -potential is given by Grosberg and Rabin. Now combining Eqs. (7) and (9) and using the numerical values relevant for the experiments ($\Delta V = +70 \text{ mV}$, $c_0 = 1 \text{ }\mu\text{M}$) and setting $\alpha = 1$, i.e., full ionization, it is obtained:

$$k_{on} = 14 \lambda_D (\text{s nm }\mu\text{M})^{-1} \quad (10)$$

which is the equation (1) reported above.

The capture radius r^* was finally computed. For this purpose the diffusion coefficient is estimated using Stokes' law:

$$D = \frac{k_B T}{6\eta\pi R_H} \quad (11)$$

where R_H is the hydrodynamic radius. Considering the dsDNA as a cylinder of radius 1 nm and length 34 nm (100bp), using the expression given by Hansen et al. (*J. Chem. Phys.* (2004) 121: 9111-9115), it was estimated that $R_H \approx 6 \text{ nm}$. Combining (11) and (4):

$$r^* = \frac{3d^2}{2l} \frac{\lambda_D R_H}{ab} \frac{e\Delta V}{k_B T} \approx 50 \text{ nm} \quad (12)$$

where $\lambda_D = 0.5 \text{ nm}$ and $k_B T \approx 25 \text{ meV}$. The capture radius is two orders of magnitude larger than the Debye length and much larger than the pore radius, hence the approximation used in Eq. (7) is justified.

ssDNA capture

The discussion of ssDNA capture is inspired by the approach developed in by Rowghanian *et al.* (*Phys. Rev. E* (2013) 87: 042723) for a barrier-limited process. This case is much more complex than the diffusion-limited case and the theory less established. The model is based on a

drift-diffusion equation using a single “reaction” coordinate r , which is the distance of one end from the pore entry. Sufficiently far from the pore the ssDNA is subject only to an attractive electrophoretic force as described by equation (1). In the vicinity of the pore at a distance $\lesssim R_g$, where R_g is the equilibrium radius of gyration there is an additional repulsive force of entropic origin: the ssDNA coil reduces its configurational entropy when the end is forced to get closer to the pore entry. If the strand is sufficiently long, the entropic repulsion dominates over the electrostatic attraction resulting in a barrier (FIG. 19).

Indicating with $U(r)$ the entropic potential the following radial current density:

$$j(r) = -D \frac{\partial c}{\partial r} + \mu c \frac{\partial V}{\partial r} - \tilde{\mu} c \frac{\partial U}{\partial r} \quad (13)$$

Where μ is the electrophoretic mobility, while $\tilde{\mu}$ is the mobility associated to a generic non-electric force, in this case the entropic repulsion. While μ does not fulfill the Einstein relation ($D \neq \mu k_B T$), the generic mobility $\tilde{\mu}$ does satisfy this relation ($\tilde{\mu} = D/k_B T$). The particle current in Eq.(13) can be rewritten as follows:

$$j(r) = -D \left(\frac{\partial c}{\partial r} - \frac{c}{k_B T} \frac{\partial F_b}{\partial r} \right) \quad (14)$$

Where:

$$F_b(r) = U(r) - \frac{\mu}{\tilde{\mu}} V(r) \quad (15)$$

Hence the problem consists in a diffusive motion of a particle in a potential F_b . Because of the violation of the Einstein relation, this potential contains also kinetic parameters as the electrophoretic mobility μ and the solvent viscosity η from $\tilde{\mu} \sim \eta^{-1}$. The potential has a minimum close to distance R_g and a maximum close to the pore entry defining a barrier height: $\Delta F_b \equiv F_b^{\max} - F_b^{\min}$. According to Kramers' theory the capture rate k_{on} depends exponentially on the barrier height:

$$k_{\text{on}} = \omega e^{-\Delta F_b / k_B T} \quad (16)$$

The barrier can be lowered by increasing the applied voltage ΔV so to strengthen the electrostatic attraction towards the pore. Eq. (15) implies that a similar effect can be obtained by increasing μ , the electrophoretic mobility of the ssDNA. One obvious way to modify μ is through a change of the ionic strength of the solution as this modifies the Debye length. As shown in Eq. (9), the electrophoretic mobility is proportional to λ_D . Note that the salt

concentration has also an effect on the ssDNA persistence length and thus on the entropic contribution to the barrier $U(r)$, however this effect is expected to be weaker. The main effect of a change in the salt concentration on the barrier height is expected to contain a term linear in λ_D :

$$\Delta F_b = a - b\lambda_D \quad (17)$$

- 5 With $a, b > 0$ which, together with (15) explains the exponential growth of k_{on} on λ_D observed in the experiments.

Table 2. Pore engineering DNA translocation from the *trans* side. Each data point is the average of at least three experiments and the error is the standard deviation. Experiments were carried out in 0.15 M NaCl, 15 mM Tris HCl, pH 7.5 solutions. The activity of the nanopores were tested by adding 0.01- 0.1 ng oligomeric protein to the *trans* chamber. A negative activity indicates that no channel insertions were observed. V_G represents the maximum applied voltage at which no gating events were observed within 30 s. DNA capture indicates that only transient current blockades were observed upon the addition of biotinylated dsDNA in complex with neutravidin. DNA translocation indicates that a dsDNA rotaxane could be formed.

15 **Table 2**

Pore variants	$I_{O+100mV}$ I_{O100Mv} (pA)	Rectification ratio	V_G , (mV)	DNA Capture	DNA Translocation
ClyA-RR-E7S	+186±2 -110±2	1.7±0.0	- 70	+	-
ClyA-RR-E11S	+214±27 -124±14	1.7±0.3	- 100	-	-
ClyA-RR-D21S	+193±9 -113±9	1.7±0.2	- 70	-	-
ClyA-RR-D21K	+149±0 -112±0	1.3±0.0	- 50	-	-
ClyA-RR-D32N	+196±5 -104±5	1.9±0.1	-150	-	-
ClyA-RR-E7S-D32N	+182±4 -104±6	1.8±0.1	- 70	+	-
ClyA-RR-E7S-D21S	+182±5 -121±3	1.5±0.1	- 70	+	-
ClyA-RR-E129R	No activity	No activity	No activity	No	No
ClyA-RR-1'R	+184±8 -101±3	1.8±0.1	-150	+	-
ClyA-RR-1'R-E7S	+176±5 -109±3	1.6±0.1	- 50	+	-

ClyA-RR-1'R-D21S	+179±9 -108±5	1.7±0.1	- 50	+	-
------------------	------------------	---------	------	---	---

Table 3: DNA molecules used in this work. 1 was formed by incubating 1a with a 20% excess of 1b and purified by affinity chromatography as described in Methods. 1* was formed by incubating 1a with a 20% excess of 1b without further purification. The complementary sequences in the two DNA strands are shown in italics. The suffix bio indicates a biotin moiety.

Table 3

Name	DNA sequence
1a	5'- GGATGA CCT GAT CCA GAT ATT TAT TAT ACA GGT CCA GCG CAC CGT CAG CCC AAT CGC ACT TTT CAC AAA AAG AGA GAG AGATCG ATT ACC /3Bio/-3' (SEQ ID NO: 5)
1b	5'- GGT AAT CGA TCT CTC TCT CTT TTT GTG AAA AGT GCG ATT GGG CTG ACG GTG CGC TGG ACC TGT ATA ATA AAT ATC TGG ATC AGG TCA TCC-3' (SEQ ID NO: 6)
1c	5'- GGT AAT CGATCT CTC TCT CTT TTT GTG AAA AGT GCG ATT GGG CTG ACG GTG CGCTGG AC-/3Bio/-3' (SEQ ID NO: 7)
1d	5'-CTG TAT AAT AAA TAT CTG GAT CAG GTC ATC C /3Bio/-3' (SEQ ID NO: 8)
2a	5'- /5Bio/CCG TAGTTT GGG ATG ACCTGA TCC AGATAT TTATTATAC AGGTCC AGC GCA CCGTCA GCC CAA TCG CACTTT TCA CAA AAA GAG AGA GAG ATC GAT TAC C-3' (SEQ ID NO: 9)
2b	5'- /5Bio/GGT AAT CGATCT CTC TCT CTT TTT GTG AAA AGT GCG ATT GGG CTG ACG GT-3' (SEQ ID NO: 10)

Table 4: Ionic selectivity of selected ClyA nanopores. Permeability ratio (P_{Na^+}/P_{Cl^-}) and reversal potential (V_r) for ClyA variant nanopores reported as average $\pm$ standard deviation. Four or more single channels were measured for each variant. The buffer used were: 15 mM TRIS.HCl pH 7.5, with 1 M NaCl in the *cis* chamber and 150 mM in the *trans* chamber.

Table 4

Pore variants	V_r , mV	P_{Na^+}/P_{Cl^-}
ClyA-AS	+11.5±0.7	1.92±0.08
ClyA-R	+11.9±1.6	1.97±0.08
ClyA-RR	+11.4±0.9	1.91±0.10

Table 5: IV curves for ClyA mutants. The electrical recordings were carried out in 0.15 M NaCl, 15 mM Tris HCl, pH 7.5, at 22°C. Each data point is the average of at least three experiments and the error is the standard deviation.

5 Table 5

Voltage (mV)	ClyA-AS	ClyA-AS-S110R (ClyA-R)	ClyA-R-D56R	ClyA-R-Q8K	ClyA-R-D64R (ClyA-RR)
-100	-138±6	-128±2	-128±2	-147±18	-111±2
-90	-126±6	-118±1	-119±2	-134±15	-104±2
-80	-115±5	-107±1	-108±2	-120±12	-96.2±1.8
-70	-102±5	-96.2±1.3	-97.3±1.3	-107±10	-87.5±1.4
-60	-89.1±4.3	-84.6±1.1	-85.9±0.9	-93.2±7.9	-78.1±1.3
-50	-75.8±3.6	-72.4±0.9	-73.2±0.3	-78.1±4.9	-67.4±1.1
-40	-61.8±2.9	-59.3±0.9	-60.4±0.4	-63.9±4.2	-56±1
-30	-47.1±2.2	-45.6±0.6	-46.2±0.2	-48.6±2.8	-43.6±0.7
-20	-31.9±1.5	-31.2±0.4	-31.7±0.3	-32.3±2	-30±1
-10	-16.2±0.7	-15.9±0.2	-16.2±0.3	-16.7±0.9	-15.4±0.2
0	0	0	0	0	0
+10	16.8±0.9	16.8±0.1	17.1±0.1	17±2	16.5±0.1
+20	34.2±1.7	34.4±0.3	35.2±0.3	35.3±3.1	34±1
+30	52.1±2.5	52.5±0.6	53.5±0.9	54.4±4.3	52.3±0.3
+40	70.5±3.4	71.6±0.7	72.9±1.1	73.8±5.7	71.5±0.3
+50	89.0±4.5	91.3±0.8	93±2	94.3±6.8	91.8±0.5
+60	108±5	112±1	114±3	115±8	112±1
+70	128±7	132±1	135±4	137±10	13±1
+80	148±8	154±1	157±5	157±12	156±1
+90	168±10	175±2	179±6	181 ±14	179±1
+100	190±13	198±1	202±8	202±16	202±1
Voltage (mV)	ClyA-R E11S	ClyA-R-D122R	ClyA-R-E129R	ClyA-R-D56R- Q8K	
-100	-165±19	-99.8±2.1	-161±24	-150±15	
-90	-150±17	-93.8±2.1	-145±23	-135±14	
-80	-136±15	-87.3±1.8	-130±20	-123±13	
-70	-120±13	-78.8±2.6	-114±18	-110±11	
-60	-105±11	-70.7±2.2	-98.3±15.1	-94.9±10.8	
-50	-88.7±9.3	-62.5±1.3	-81.2±11	-81±9	
-40	-71.9±7.3	-52.3±0.9	-65.4±8.9	-65.3±7.9	
-30	-54.6±5.3	-41.1±0.5	-49.2±6.5	-49.9±6.4	

-20	-36.9±3.6	-28.6±0.4	-32.9±4.4	-33±5	
-10	-18.6±1.8	-14.9±0.2	-16.6±2.4	-16.5±2.5	
0	0	0	0	0	
+10	19±2	16±0	16.8±2.5	17.9±2.3	
+20	38.4±3.4	33.3±0.5	33.8±5.1	35.4±5.6	
+30	58±5	51.6±0.5	50.7±7.6	54±9	
+40	77.7±6.9	71.1±0.8	67.6±10.2	72.5±12.5	
+50	97.8±8.2	91.6±0.8	84.6±12.6	91.7±15.9	
+60	119±10	113±1	101±15	114±17	
+70	140±11	135±1	118±18	133±20	
+80	159 ±13	158±2	136±20	154±23	
+90	181 ±15	182±2	153±23	182±20	
+100	201±13	207±2	171±26	207±20	

Table 5 continued

Voltage (mV)	ClyA-RR-E7S	ClyA-RR-E11S	ClyA-RR-D21S	ClyA-RR-D21K	ClyA-RR-D32N
-100	-111±4	-128±11	-113±9	-120±1	-108±1
-90	-103±3	-119±10	-106±8	-109±0	-101±1
-80	-95.4±3.4	-109±9	-96.6±7.9	-99.1±0.3	-93.2±0.9
-70	-87±3	-98.9±8.2	-87.6±6.5	-88.1±0.1	-84.7±0.7
-60	-77.3±2.8	-87.9±7.5	-77.9±5.4	-76.6±0.2	-75.5±0.6
-50	-66.3±2.2	-75.5±6.2	-67.1±4.5	-65±0	-65.2±0.5
-40	-54.7±1.9	-62.5±5.2	-55.2±3.8	-53.2±0.1	-54.2±0.5
-30	-42.3±1.4	-48.3±4	-42.3±3.3	-40.5±0.1	-42.1±0.4
-20	-28.9±1	-33.2±2.8	-29±2	-27.5±0	-29±0
-10	-15±0	-17±1	-15.1±0.9	-13.9±0	-15±0
0	0	0	0	0	0
+10	15±1	18±1	16±1	14.3±0	15.6±0.6
+20	31.2±2.4	36.8±3.1	32.5±2.2	29.2±0	32.2±1.3
+30	49.1±2	56.3±4.6	50.1±3.1	44.3±0.1	49.6±2.1
+40	66.2±3.7	76.8±6.6	67.2±5.1	60±0	67.9±2.8
+50	85.7±3.3	98±8	87.3±5.5	75.6±0.5	87±4
+60	105±4	120±11	107±6	92.2±0.1	107±5
+70	125±4	142±13	127±7	109±0	127±5
+80	145±5	165±15	148±8	125±0	149±6
+90	166±5	189±17	170±9	142±0	171±7
+100	188±6	214±19	193±11	160±0	198±4

Voltage (mV)	ClyA-RR-E7S-D21S	ClyA-RR-E7S-D32N	ClyA-RR-1R (ClyA-3R)	ClyA-3R-E7S	ClyA-3R-D21S
-100	-120±4	-104±6	-112±9	-109±3	-108±5
-90	-109±1	-96.9±5.6	-103±12	-101±2	-101±4
-80	-99.9±2.1	-89.2±4.7	-93.5±11.8	-93.2±2.9	-93.1±4
-70	-88.6±1	-80.9±4.2	-86±10	-84.8±1.1	-83.4±2
-60	-80.4±1.7	-71.9±3.5	-77.6±8.2	-74.3±0.9	-73.2±1.3
-50	-67.4±2.7	-62±3	-65.9±7.1	-63.7±1	-63.3±1
-40	-56.2±2	-51.4±2.3	-54.6±5.6	-52.8±1	-52.3±0.8
-30	-43.4±1.1	-39.8±1.7	-42.5±3.6	-40.6±1	-40.6±0.6
-20	-28.9±1.6	-27.4±1.2	-30±3	-28.1±0.5	-28±0
-10	-13.5±1	-14.2±0.5	-14.9±1.7	-14.3±0.3	-14.4±0.2
0	0	0	0	0	0
+10	16.4±2.4	15±0	16.1±0.8	15.1±0.5	15.3±0.3
+20	32.2±1.4	30.7±1	32.4±2.1	30.9±1.1	31.5±1.1
+30	50.3±2.1	47.4±1.5	50±2	47.5±1.5	48.3±1.8
+40	68±2	64.7±1.9	68.7±2.7	64.5±2	65.8±2.4
+50	85.8±1.1	82.7±2.4	88±3	81.7±2.5	83.7±3.3
+60	103±1	101±3	106±5	99.5±2.9	102±4
+70	122±4	121±3	126±5	118±3	121±6
+80	143±0	140±3	149±9	137±4	140±6
+90	163±2	160±3	170±5	156±4	160±7
+100	184±0	182±4	191±11	176±5	179±9

Table 6: IV curves of ClyA variants under asymmetric salt concentrations. Four or more single channels were measured for each variant. Each data is reported as the average $\pm$ standard deviation. The buffer used was 15 mM TRIS.HCl pH 7.5, while the *cis* chamber contained 1 M NaCl and the *trans* chamber 150 mM. The electrical recordings were carried out in 0.15 M NaCl, 15 mM Tris HCl, pH 7.5, at 22°C. Data were recorded by applying a 2-kHz low-pass Bessel filter and using a 100 μ s (10 kHz) sampling rate.

Table 6

IV	ClyA Ionic permeability Open pore current, pA (Average $\pm$ Standard Deviation)		
Voltage (mV)	ClyA-AS	ClyA-R	ClyA-RR
20	26.5±0.7	36.7±14.1	32.4±4.3
19	23.1±0.9	32.5±13	28.6±2.7
18	19.8±0.5	27.6±12.8	25.2±2.5

17	16.6±0.9	23.4±10.8	21.3±1.8
16	13.6±1.8	17.9±10.7	16.6±1.2
15	9.9±1.9	14.4±9.7	12.8±1.9
14	7.2±1.2	7.8±9.3	10.2±1.2
13	4.4±1.1	2.9±8.9	7.2±1.4
12	2.5±1.4	-1.7±9.4	1.8±1.3
11	-0.7±2.5	-5.6±8.6	-0.8±1.9
10	-3.8±2.7	-12.7±7.3	-4±1
9	-7.3±2.7	-15.6±8	-9.3±3.1
8	-10.7±1.5	-22.3±6.3	-11.9±0.5
7	-13.4±4.3	-24.5±5.9	-15.5±2.6
6	-16.2±0.9	-31.2±5.8	-19.8±3.2
5	-18±2	-35.2±4.5	-23.1±3.1
4	-22.3±2.5	-40.4±5.2	-25.7±1.7
3	-25±2	-43.7±3.5	-30.1±2.9
2	-27.8±3.1	-51.2±4.1	-33.8±4.5
1	-30.5±3.1	-55.6±2.1	-36.9±4.8
0	-34.9±2.7	-60.7±2	-40.7±5
-1	-37.1±3.5	-65.1±2.6	-44.4±3.8
-2	-41±3	-68.8±3.8	-48.2±4.2
-3	-42.1±3.9	-74.8±3.6	-51.3±6.5
-4	-46.2±4.2	-79.8±2.1	-54.8±7.9
-5	-48.8±4.2	-85.2±2.5	-57.8±6.5

IV			
ClyA Ionic permeability			
Open pore current, pA (Average ± Standard Deviation)			
Voltage (mV)	ClyA-AS	ClyA-R	ClyA-RR
-6	-51.5±3.5	-90±3	-61.2±7.8
-7	-55.1±6.3	-94±4	-66.2±7.3
-8	-57.8±5.5	-100±3	-68.6±10.7
-9	-61±4	-103±3	-73.1±8.3
-10	-62.8±4.9	-109±4	-76.5±7.9
-11	-66.2±5	-114±4	-80.1±9.1
-12	-69.7±6	-117±4	-83.6±9.9
-13	-74.7±5.5	-123±4	-86.6±8.7
-14	-74.8±6.1	-129±5	-91.1±11.2
-15	-78.3±5.7	-134±7	-93.5±10.7
-16	-80.2±6.2	-137±8	-96.7±9.7
-17	-84.2±6.4	-144±7	-100±13
-18	-87.6±7.6	-148±8	-104±12

-19	-90.4±7.7	-153±8	-108±12
-20	-92.4±7.3	-158±8	-112±11

Table 7: ssDNA (**1a**) and dsDNA (**1**) translocation through ClyA-RR nanopores. Three or more single channels were measured for each condition. Data are reported as the average $\pm$ standard deviation. The electrical recordings were carried out in 15 mM Tris- HCl, pH 7.5 at 22°C. Data were recorded by applying a 10-kHz low-pass Bessel filter and using a 20 μ s (50 kHz) sampling rate.

Table 7

ssDNA (1a)			
[NaCl] (M)	I_{RES}	τ_{off} (ms)	τ_{on} (ms)
0.15	0.92±0.00	0.54±0.28	8.5±1.1
0.3	0.89±0.01	0.18±0.04	44±1
0.5	0.88±0.02	0.12±0.02	112±14
1	0.82±0.01	0.13±0.01	232±36
2	0.84±0.01	0.12±0.02	393±17
2.5	0.78±0.01	0.18±0.02	500±50
dsDNA (1)			
[NaCl] (M)	I_{RES}	τ_{off} (ms)	τ_{on} (ms)
0.15	0.92±0.00	0.29±0.07	40±13
0.6	0.83±0.03	0.26±0.09	162±31
1	0.76±0.01	0.26±0.09	214±18
2	0.75±0.04	0.33±0.07	532±52
2.5	0.75±0.01	0.60±0.48	641±37

10

SEQUENCE LISTING:

Description	Sequence
Protein sequence for <i>S. typhi</i> ClyA (ClyA-WT) SEQ ID NO: 1	MTGIFAEQTVEVVKSAIETADGALDLYNKYLDQVIPWKTFDETIKELSRFKQE YSQEASVLVGDIKVLMLDSQDKYFEATQTVYEWCGVVTQLLSAYIILFDEYNE KKASAQKDILIRILDDGVKKLNEAQKSLTSSQSFNNASGKLLALDSQLTND SEKSSYFQSQVDRIRKEAYAGAAAGIVAGPFGLIISYSIAAGVIEGKLIPELN NRLKTVQNFFTSLSATVKQANKDIDAANKLKLATEIAAIGEIKTETETTRFYVD YDDLMLSLKGAACKMINTCNEYQQRHGKKTLEVPDV
Protein sequence for ClyA-AS SEQ ID NO: 2	MTGIFAEQTVEVVKSAIETADGALDLYNKYLDQVIPWKTFDETIKELSRFKQE YSQEASVLVGDIKVLMLDSQDKYFEATQTVYEWAGVVTQLLSAYIQLFDGYNE KKASAQKDILIRILDDGVKKLNEAQKSLTSSQSFNNASGKLLALDSQLTND SEKSSYFQSQVDRIRKEAYAGAAAGIVAGPFGLIISYSIAAGVIEGKLIPELN NRLKTVQNFFTSLSATVKQANKDIDAANKLKLATEIAAIGEIKTETETTRFYVD YDDLMLSLKGAACKMINTSNEYQQRHGKKTLEVPDVGSSYHHHHH*
Nucleotide sequence for <i>S.</i>	CCTGCGTAGATAAGCAGGAAGCAGGCAGTATTTCCAGCTTCTGGAATGTTAAA GCTACAAAAGTTGTCTGGAGGTAATAGGTAAGAATACTTTATAAACAGGTAC

<i>typhi</i> ClyA (ClyA-WT) SEQ ID NO: 3	TTAATTGCAATTTATATATTTAAAGAGGCAAATGATTATGACCGGAATATTTG CAGAACAACTGTAGAGGTAGTTAAAAGCGCGATCGAAACCGCAGATGGGGCA TTAGATCTTTATAACAAATACCTCGACCAGGTCATCCCCTGGAAGACCTTTGA TGAAACCATAAAAAGAGTTAAGCCGTTTTAAACAGGAGTACTCGCAGGAAGCTT CTGTTTTAGTTGGTGATATTAAAGTTTTGCTTATGGACAGCCAGGACAAGTAT TTTGAAGCGACACAACTGTTTATGAATGGTGTGGTGTCTGTGACGCAATTACT CTCAGCGTATATTTTACTATTTGATGAATATAATGAGAAAAAAGCATCAGCCC AGAAAGACATTCTCATTAGGATATTAGATGATGGTGTCAAGAAACTGAATGAA GCGCAAAAATCTCTCCTGACAAGTTCACAAAGTTTCAACAACGCTTCCGGAAA ACTGCTGGCATTAGATAGCCAGTTAACTAATGATTTTTTCGGAAAAAAGTAGTT ATTTCCAGTCACAGGTGGATAGAATTCGTAAGGAAGCTTATGCCGGTGTGCA GCCGGCATAGTCGCCGGTCCGTTTGGATTAATTATTTTCTATTCTATTGCTGC GGCGTGATTGAAGGGAAATTGATTCCAGAATTGAATAACAGGCTAAAAACAG TGCAAAATTTCTTTACTAGCTTATCAGCTACAGTGAAACAAGCGAATAAAGAT ATCGATGCGGCAAAATTGAAATTAGCCACTGAAATAGCAGCAATTGGGGAGAT AAAAACGGAAACCGAAACAACCAGATTCTACGTTGATTATGATGATTTAATGC TTTCTTTATTAAAAGGAGCTGCAAGAAAAATGATTAAACACCTGTAATGAATAC CAACAAAGACACGGTAAGAAGACGCTTTTCGAGGTTCTTGACGTCTGATACAT TTTCATTGATCTGTGTACTTTTAACGCCCGATAGCGTAAAGAAAATGAGAGA CGGAGAAAAAGCGATATTCAACAGCCCGATAAACAAGAGTCGTTACCGGGCTG ACGAGGTTATCAGGCGTTAAGCTGGTAG
Nucleotide sequence for ClyA- AS SEQ ID NO: 4	ATGACGGGTATCTTTGCGGAACAGACGGTGGAAGTTGTGAAAAGTGCATTGA AACGGCTGACGGTGCGCTGGACCTGTATAATAAATATCTGGATCAGGTCATCC CGTGAAAAACCTTTGACGAAACGATTAAAGAACTGAGCCGTTTCAAACAGGAA TACAGTCAAGAAGCGTCCGTCCTAGTGGGCGATATCAAAGTGCTGCTGATGGA TTCTCAGGACAAATATTTTGAAGCTACCCAAACGGTTTACGAATGGGCGGGTG TGGTTACCCAGCTGCTGTCCGCATATATTCAGCTGTTCCGATGGATACAATGAG AAAAAAGCGAGCGCGCAGAAAGACATTCTGATCCGCATTCTGGATGACGGCGT GAAAAAACTGAATGAAGCCAGAAAATCGCTGCTGACCAGCTCTCAATCATTTA ACAATGCCTCGGGTAACTGCTGGCACTGGATAGCCAGCTGACGAACGACTTT TCTGAAAAAAGTTCTTATTACCAGAGCCAAGTCGATCGTATTCGTAAAGAAGC CTACGCAGGTGCCGACGAGGTATTGTGGCCGGTCCGTTCCGGTCTGATTATCT CATATTCAATTGCTGCGGGCGTTGTGGAAGGTAACTGATTCCGGAACGTAAC AATCGTCTGAAAACCGTTTCAAGAACTTTTTCACCAAGTCTGTCTGCTACGGTCAA ACAAGCGAATAAAGATATCGACGCCGCAAACTGAACTGGCCACGGAAATCG CTGCGATTGGCGAAATCAAAACCGAAACGGAAACCGCGCTTTTATGTTGAT TACGATGACCTGATGCTGAGCCTGCTGAAAGGTGCCGCGAAGAAAATGATTAA TACCTCTAATGAATATCAGCAGCGTCACGGTAGAAAAACCTGTTTGAAGTCC CGGATGTGGGCAGCAGCTACCACCATCATCACCCTAAAAGCTT

OTHER EMBODIMENTS

All of the features disclosed in this specification may be combined in any combination.

Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

From the above description, one skilled in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the disclosure to adapt it to various usages and conditions.

Thus, other embodiments are also within the claims.

EQUIVALENTS

While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.

All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.

All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.

The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”

The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A

only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.

As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

CLAIMS

What is claimed is:

1. A modified ClyA nanopore comprising a *cis* opening, a mid-section, and a *trans* opening, wherein an internal surface of the *cis* opening comprises a first positively-charged amino acid substitution; an internal surface of the mid-section comprises a second positively-charged amino acid substitution; and the *trans* opening comprises an electronegative constriction.
2. The modified ClyA nanopore of claim 1, wherein the first positively-charged amino acid substitution is positioned within the *cis* opening so as to permit capture of a deoxyribonucleic acid into the modified ClyA nanopore.
3. The modified ClyA nanopore of claim 2, wherein the second positively-charged amino acid substitution is positioned within the mid-section so as to permit translocation of the deoxyribonucleic acid through the modified ClyA nanopore.
4. The modified ClyA nanopore of any one of claims 1-3, wherein the first and second positively-charged amino acid substitutions each includes an arginine.
5. The modified ClyA nanopore of any one of claims 1-4, wherein the first positively-charged amino acid substitution corresponds to a S110R mutation in the amino acid sequence of ClyA-AS.
6. The modified ClyA nanopore of any one of claims 1-5, wherein the second positively-charged amino acid substitution corresponds to a D64R mutation in the amino acid sequence of ClyA-AS.
7. The modified ClyA nanopore of any one of claims 1-6, wherein the modified ClyA pore is a dodecameric pore.
8. A composition comprising a modified ClyA nanopore of any one of claims 1-7.
9. The composition of claim 8, further comprising an artificial membrane, wherein the modified ClyA nanopore is present in the artificial membrane.
10. The composition of claim 8 or 9, further comprising a low ionic strength solution.
11. The composition of claim 10, wherein the low ionic strength solution is a salt solution having an ionic strength of about 50 mM to about 1 M.
12. The composition of claim 11, wherein the ionic strength is about 150 mM.
13. The composition of claim 11 or 12, wherein the salt solution comprises sodium chloride (NaCl).
14. A method of translocating a DNA through a ClyA nanopore comprising:
- a. providing, in a low ionic strength solution, a modified ClyA nanopore of any one of claims 1-13 and an artificial membrane, wherein the modified ClyA nanopore is present in an

artificial membrane such that the *cis* opening of the modified ClyA nanopore is present in a *cis* side of the low ionic strength solution and the *trans* opening of the modified ClyA nanopore is present in a *trans* side of the low ionic strength solution;

b. providing a DNA in the *cis* side of the low ionic strength solution; and

5 c. applying an electrical potential across the modified ClyA nanopore, thereby translocating the DNA through the modified ClyA nanopore from the *cis* side to the *trans* side.

15. The method of claim 14, wherein the low ionic strength solution is a salt solution having an ionic strength of about 150 mM to about 300 mM.

16. The method of claim 15, wherein the ionic strength is about 150 mM.

10 17. The method of claim 15 or 16, wherein the salt solution comprise sodium chloride (NaCl).

18. The method of any one of claims 14-17, wherein the DNA is a single-stranded DNA.

15 19. The method of any one of claims 14-17, wherein the DNA is a double-stranded DNA.

20. The method of any one of claims 14-19, wherein the method is used for DNA sequencing.

21. A modified ClyA nanopore subunit polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence as set forth in SEQ ID NO: 1 (corresponding to the amino acid sequence of wild-type ClyA) or in SEQ ID NO: 2 (corresponding to the amino acid sequence of ClyA-AS), and wherein the amino acid sequence comprises a first positively-charged amino acid substitution at a position within a range of 106-78 of SEQ ID NO: 1 or SEQ ID NO: 2 and a second positively-charged amino acid substitution at a position within a range of 41-74 of SEQ ID NO: 1 or SEQ ID NO: 2.

25 22. The modified ClyA nanopore subunit polypeptide of claim 21, wherein the amino acids at positions 1-32 of SEQ ID NO: 1 or SEQ ID NO: 2 yield a net negative charge.

23. The modified ClyA nanopore subunit polypeptide of claim 21 or 22, wherein the first positively-charged amino acid substitution is located at position 110 of SEQ ID NO: 1 or SEQ ID NO: 2.

30 24. The modified ClyA nanopore subunit polypeptide of any one of claims 21-23, wherein the second positively-charged amino acid substitution is located at position 64 of SEQ ID NO: 1 or SEQ ID NO: 2.

25. The modified ClyA nanopore subunit polypeptide of any one of claims 21-24, wherein the first and second positively-charged amino acid substitutions each independently includes an arginine, a histidine, or a lysine.

26. A polynucleotide comprising a nucleotide sequence encoding the modified ClyA nanopore subunit polypeptide of any one of claims 21-25.

27. A homo-multimeric modified ClyA nanopore comprising a plurality of modified ClyA nanopore subunit polypeptides of any one of claims 21-25.

28. The homo-multimeric modified ClyA nanopore of claim 27, comprising 12-14 of the modified ClyA nanopore subunit polypeptides.

29. The homo-multimeric modified ClyA nanopore of claim 27 or 28, wherein the first positively-charged amino acid substitutions of the modified ClyA nanopore subunit polypeptides are positioned within a first opening of the homo-multimeric modified ClyA nanopore so as to permit capture of a negatively charged polymer within a solution exposed to the first opening.

30. The homo-multimeric modified ClyA nanopore of claim 29, wherein the second positively-charged amino acid substitutions of the modified ClyA nanopore subunit polypeptides are positioned within a mid-section of the homo-multimeric modified ClyA nanopore so as to permit translocation of the negatively charged polymer through the nanopore.

31. A hetero-multimeric modified ClyA nanopore comprising at least one modified ClyA nanopore subunit polypeptide of any one of claims 21-25.

32. The hetero-multimeric modified ClyA nanopore of claim 31, comprising 12-14 of ClyA nanopore subunit polypeptides including said at least one modified ClyA nanopore subunit polypeptide.

33. The hetero-multimeric modified ClyA nanopore of claim 31 or 32, wherein the first positively-charged amino acid substitution of the modified ClyA nanopore subunit polypeptide is positioned within a first opening of the hetero-multimeric modified ClyA nanopore so as to permit capture of a negatively charged polymer within a solution exposed to the first opening.

34. The hetero-multimeric modified ClyA nanopore of claim 33, wherein the second positively-charged amino acid substitution of the modified ClyA nanopore subunit polypeptide is positioned within a mid-section of the hetero-multimeric modified ClyA nanopore so as to permit translocation of the negatively charged polymer through the nanopore.

35. A modified ClyA nanopore comprising a first opening, a mid-section, a second opening, and a lumen extending from the first opening through the mid-section to the second opening, wherein a luminal surface of the first opening comprises a first positively-charged amino acid substitution and a luminal surface of the mid-section comprises a second positively charged amino acid substitution, and wherein a luminal surface of the second opening defines an electronegative constriction.

36. The modified ClyA nanopore of claim 35, wherein the distance within the lumen from the first positively-charged amino acid substitution to the second positively charged amino acid substitution is in a range of 0.5 nm to 10 nm.

37. The modified ClyA nanopore of claim 35 or 36, comprising a subunit polypeptide having an amino acid sequence that is at least 95% identical to the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2.

38. The modified ClyA nanopore of claim 35 or 36, comprising a subunit polypeptide having up to ten substitutions compared with the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 including the first and second positively-charged amino acid substitutions.

39. The modified ClyA nanopore of any one of claims 35-38, wherein the first positively-charged amino acid substitution is of an amino acid selected from the group consisting of amino acids 110, 106, 114, 121, 122, 129, 85, 78, 268, 267, 265, and 258 of SEQ NO: 1 or SEQ ID NO: 2.

40. The modified ClyA nanopore of any one of claims 35-39, wherein the second positively-charged amino acid substitution is of an amino acid selected from the group consisting of amino acids 74, 71, 64, 53, 161, 158, 46, 42, 41 of SEQ NO: 1 or SEQ ID NO: 2.

41. The modified ClyA nanopore of any one of claims 35-40, wherein first positively-charged amino acid substitution is positioned within the first opening so as to permit capture of a negatively charged polymer within a solution exposed to the first opening.

42. The modified ClyA nanopore of claim 41, wherein the second positively-charged amino acid substitution is positioned within the mid-section so as to permit translocation of the negatively charged polymer through the lumen of the pore.

43. The modified ClyA nanopore of claim 41 or 42, wherein the negatively charged polymer is a nucleic acid.

44. The modified ClyA nanopore of claim 43, wherein the nucleic acid is a deoxyribonucleic acid.

45. The modified ClyA nanopore of claim 44, wherein the deoxyribonucleic acid is double-stranded.

46. The modified ClyA nanopore of claim 44, wherein the deoxyribonucleic acid is single-stranded.

47. The modified ClyA nanopore of any one of claims 35-46, wherein the modified ClyA nanopore is a dodecameric pore .

48. The modified ClyA nanopore of any one of claims 35-46, wherein the modified ClyA nanopore is a 13-mer pore .

49. A composition comprising at least one modified ClyA nanopore of any one of claims 27-48.

50. The composition of claim 49, further comprising a membrane, wherein the modified ClyA nanopore is present in the membrane.

5 51. The composition of claim 49 or 50, further comprising a polynucleotide binding protein.

52. The composition of claim 51, wherein the polynucleotide binding protein is coupled to the modified ClyA nanopore.

10 53. The composition of any one of claims 49-52, further comprising a low ionic strength solution.

54. The composition of claim 52, wherein the low ionic strength solution is a salt solution having an ionic strength of about 150 mM to about 300 mM.

55. The composition of claim 52 or 53, wherein the salt solution comprise sodium chloride (NaCl).

15 56. A method of characterizing a target polynucleotide, the method comprising

(a) providing, in a low ionic strength solution of about 150 mM to about 300 mM, a modified ClyA nanopore of any one of claims 27-48 and a membrane, wherein the modified ClyA nanopore is present in the membrane;

(b) adding in the low ionic strength solution of step (a) the target polynucleotide; and

20 (c) measuring, during application of a potential across the nanopore, ion flow through the modified ClyA nanopore, wherein the ion flow measurements are indicative of one or more characteristics of the target polynucleotide.

57. The method of claim 56, wherein the one or more characteristics are selected from (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the
25 sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide, and (v) whether or not the target polynucleotide is modified, and thereby characterizing the target polynucleotide.

58. The method of claim 56 or 57, further comprising adding a polynucleotide binding protein in the low ionic strength solution of step (b) such that the polynucleotide binding protein
30 binds to the target polynucleotide and controls the movement of the target polynucleotide through the modified ClyA nanopore.

59. The method of any one of claims 56-58, wherein the target polynucleotide is a single-stranded DNA.

60. The method of any one of claims 56-58, wherein the target polynucleotide is a double-stranded DNA.

61. The method of any one of claims 56-60, wherein the ion flow measurements comprise a current measurement , an impedance measurement, a tunneling measurement or a
5 field effect transistor (FET) measurement.

62. The method of any one of claims 56-61, wherein the low ionic strength solution comprises sodium chloride.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

6/20




FIG. 6




FIG. 7




FIG. 8




FIG. 9

10/20




FIG. 10




FIG. 11

12/20




FIG. 12




FIG. 13

14/20






FIG. 14


15/20

**FIG. 15**

16/20

**FIG. 16**

17/20

**FIG. 17**

18/20




FIG. 18




FIG. 19




FIG. 20

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2016/001841

A. CLASSIFICATION OF SUBJECT MATTER
INV. G01N33/487
ADD. C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, EMBASE, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014/153625 A1 (UNIV LEUVEN KATH [BE]) 2 October 2014 (2014-10-02)	1-4, 7-11,13, 14, 17-19, 35-38, 47-53
Y	p.2 par.2, 3,p.18 par.3- p.19 par.3 ----- -/--	5,12,15, 16, 20-23, 25-34, 39-46, 54-62

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 May 2017

Date of mailing of the international search report

31/05/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Bonello, Steve

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2016/001841

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2015/051378 A1 (UNIV WASHINGTON CT COMMERCIALI [US]) 9 April 2015 (2015-04-09)	1-4, 35-38, 41-48
Y	p.6 par.3, p.17 par.3, p.18 par.3-p.19 par.3	5, 12, 15, 16, 20-23, 25-34, 39-46, 54-62
Y	----- WO 2015/166276 A1 (OXFORD NANOPORE TECH LTD [GB]) 5 November 2015 (2015-11-05)	5, 12, 15, 16, 20-23, 25-34, 39-46, 54-62
	p.10 par.2-p.11 par.1, p.36 par.3	
X	----- Lorenzo Franceschini ET AL: "A nanopore machine promotes the vectorial transport of DNA across membranes", Nature Communications, 1 September 2013 (2013-09-01), page 2415, XP055372337, London DOI: 10.1038/ncomms3415 Retrieved from the Internet: URL: https://www.nature.com/articles/ncomms3415.pdf [retrieved on 2017-05-12]	1-4, 35-38, 41-48
A	p.2 col.1 par.3-col.2 par.1	5-13, 21-34, 39, 40, 49-55
A	----- GUASCH A ET AL: "Detailed architecture of a DNA translocating machine: the high-resolution structure of the bacteriophage phi29 connector particle", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 315, no. 4, 25 January 2002 (2002-01-25), pages 663-676, XP004486231, ISSN: 0022-2836, DOI: 10.1006/JMBI.2001.5278 p.667 col.2 par.5 - p.668 col.2 par.1, p.669 col.2 par.2 - p.670 col.1 par.2. -----	1-13, 21-55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2016/001841

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2016/001841

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2014153625 A1	02-10-2014	AU 2014245783 A1 CA 2904202 A1 CN 105358567 A EP 2978773 A1 JP 2016516735 A US 2016053300 A1 US 2016370358 A1 WO 2014153625 A1	01-10-2015 02-10-2014 24-02-2016 03-02-2016 09-06-2016 25-02-2016 22-12-2016 02-10-2014
WO 2015051378 A1	09-04-2015	NONE	
WO 2015166276 A1	05-11-2015	CN 106459159 A CN 106574300 A EP 3137490 A1 EP 3137627 A1 US 2017058337 A1 US 2017058338 A1 WO 2015166275 A1 WO 2015166276 A1	22-02-2017 19-04-2017 08-03-2017 08-03-2017 02-03-2017 02-03-2017 05-11-2015 05-11-2015